<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HE6148B3FFD464846BA4753CD18BE602D" public-private="public" key="H" bill-type="olc">
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 4697 IH: Protecting Pandemic and All-Hazards Preparedness Act of 2023</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-07-18</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code>
<congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session>
<legis-num display="yes">H. R. 4697</legis-num>
<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
<action display="yes">
<action-date date="20230718">July 18, 2023</action-date>
<action-desc><sponsor name-id="S001216">Ms. Schrier</sponsor> (for herself, <cosponsor name-id="E000215">Ms. Eshoo</cosponsor>, <cosponsor name-id="P000034">Mr. Pallone</cosponsor>, <cosponsor name-id="D000197">Ms. DeGette</cosponsor>, <cosponsor name-id="S001145">Ms. Schakowsky</cosponsor>, <cosponsor name-id="M001163">Ms. Matsui</cosponsor>, <cosponsor name-id="C001066">Ms. Castor of Florida</cosponsor>, <cosponsor name-id="S001168">Mr. Sarbanes</cosponsor>, <cosponsor name-id="T000469">Mr. Tonko</cosponsor>, <cosponsor name-id="C001067">Ms. Clarke of New York</cosponsor>, <cosponsor name-id="C001097">Mr. Cárdenas</cosponsor>, <cosponsor name-id="R000599">Mr. Ruiz</cosponsor>, <cosponsor name-id="P000608">Mr. Peters</cosponsor>, <cosponsor name-id="D000624">Mrs. Dingell</cosponsor>, <cosponsor name-id="V000131">Mr. Veasey</cosponsor>, <cosponsor name-id="K000382">Ms. Kuster</cosponsor>, <cosponsor name-id="K000385">Ms. Kelly of Illinois</cosponsor>, <cosponsor name-id="B001300">Ms. Barragán</cosponsor>, <cosponsor name-id="B001303">Ms. Blunt Rochester</cosponsor>, <cosponsor name-id="S001200">Mr. Soto</cosponsor>, <cosponsor name-id="C001119">Ms. Craig</cosponsor>, <cosponsor name-id="T000482">Mrs. Trahan</cosponsor>, and <cosponsor name-id="F000468">Mrs. Fletcher</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc>
</action>
<legis-type>A BILL</legis-type>
<official-title display="yes">To amend the Public Health Service Act to reauthorize certain programs with respect to public health security and all-hazards preparedness and response related to the Administration for Strategic Preparedness and Response and certain programs with respect to public health security and all-hazards preparedness and response related to the Centers for Disease Control and Prevention, and for other purposes.</official-title>
</form>
<legis-body id="H28F36AB3065E4A97ADBBDE6BD7CA60E6" style="OLC">
<section commented="no" display-inline="no-display-inline" id="HA15C3191A3324934BA10098811B82609" section-type="section-one"><enum>1.</enum><header display-inline="yes-display-inline">Short title; table of contents</header>
<subsection commented="no" display-inline="no-display-inline" id="H00DFA39B04CB46BE821D9C9D4ECB86B4"><enum>(a)</enum><header display-inline="yes-display-inline">Short title</header><text display-inline="yes-display-inline">This Act may be cited as the <quote><short-title>Protecting Pandemic and All-Hazards Preparedness Act of 2023</short-title></quote> or the <quote><short-title>Protecting PAHPA Act of 2023</short-title></quote>.</text></subsection> <subsection commented="no" display-inline="no-display-inline" id="H6C2504A49C4742FC81EED613D32B0E87"><enum>(b)</enum><header display-inline="yes-display-inline">Table of contents</header><text display-inline="yes-display-inline">The table of contents for this Act is as follows:</text>
<toc container-level="legis-body-container" quoted-block="no-quoted-block" lowest-level="section" regeneration="yes-regeneration" lowest-bolded-level="division-lowest-bolded">
<toc-entry idref="HA15C3191A3324934BA10098811B82609" level="section">Sec. 1. Short title; table of contents.</toc-entry>
<toc-entry idref="H4A0DAC1114604258B02D2CAF3D001FEB" level="title">Title I—Preparing for and responding to public health security threats</toc-entry>
<toc-entry idref="H4F4479711B1248FB919FBA718DE42C85" level="section">Sec. 101. National health security strategy.</toc-entry>
<toc-entry idref="HE2E369993C25430D80C903977A1B84EA" level="section">Sec. 102. Protection of national security from threats.</toc-entry>
<toc-entry idref="HB44D71BA14044BA19033CF80265090B0" level="section">Sec. 103. Partnerships for State and regional hospital preparedness to improve surge capacity.</toc-entry>
<toc-entry idref="H9B933D8E1CFC4C219C163A034FD995AC" level="section">Sec. 104. Guidelines for regional health care emergency preparedness and response systems.</toc-entry>
<toc-entry idref="H20539C9D239D472ABDF09CCBF9297AC2" level="section">Sec. 105. Strategic National Stockpile.</toc-entry>
<toc-entry idref="HDE1C14AC9FFF431BB19059C10ED726D0" level="section">Sec. 106. Diagnostic testing preparedness plan.</toc-entry>
<toc-entry idref="H3356F683BF9C4731BEAE3E842D6CA4FC" level="section">Sec. 107. Biomedical Advanced Research and Development Authority.</toc-entry>
<toc-entry idref="H59DBE545497C4319A22E0D93C0AA6127" level="section">Sec. 108. Ensuring collaboration and coordination in medical countermeasure development.</toc-entry>
<toc-entry idref="H4D17EDC4CA3741C4852BF15B2B0D7CC8" level="section">Sec. 109. Review of ASPR efforts to ensure supply chain resiliency and accountability.</toc-entry>
<toc-entry idref="HE2B115CD84CD4D108A038649C33F88C2" level="section">Sec. 110. Review of HHS efforts To ensure rapid production and domestic manufacturing capacity of medical countermeasures.</toc-entry>
<toc-entry idref="H5675F4F3FE7C4980BDE38620392FC133" level="section">Sec. 111. Crisis standards of care.</toc-entry>
<toc-entry idref="HB0D5092BA58245A5A402044F27AE18AA" level="title">Title II—Ensuring workforce to prepare for and respond to public health security threats</toc-entry>
<toc-entry idref="H96C64833473E4826ABE45A86081901C6" level="section">Sec. 201. Emergency system for advance registration of volunteer health professional.</toc-entry>
<toc-entry idref="HBCD978D78A904392A461BA3B452E88CB" level="section">Sec. 202. Military and civilian partnership for trauma readiness.</toc-entry>
<toc-entry idref="H953FF3EC862743C0A8B138CC2F02E3BD" level="section">Sec. 203. National advisory committees on disasters.</toc-entry>
<toc-entry idref="H11240BD8DC084E75A7DA34D88CE6499F" level="section">Sec. 204. National Disaster Medical System.</toc-entry>
<toc-entry idref="HE977F759A3474B4099BE8998EA8F3256" level="section">Sec. 205. Volunteer Medical Reserve Corps.</toc-entry>
<toc-entry idref="H3EB72BACF4D8464AAF530AB7F935AE67" level="title">Title III—Preparing for and responding to public health security threats</toc-entry>
<toc-entry idref="HEDC64260F33F4E13A9EAC42F9EFCDAC7" level="section">Sec. 301. Improving State and local public health security.</toc-entry>
<toc-entry idref="H811F0B9502374F8CA44C04652065CD12" level="section">Sec. 302. Facilities and capacities of the Centers for Disease Control and Prevention to combat public health security threats.</toc-entry>
<toc-entry idref="HCA79BE4D146748A5BE699DDD2ACF8905" level="section">Sec. 303. Monitoring and distribution of certain medical countermeasures.</toc-entry>
<toc-entry idref="H76BED0316CBA49C29A05C8967D6A4A26" level="section">Sec. 304. Enhanced control of dangerous biological agents and toxins.</toc-entry>
<toc-entry idref="H7DF821180ACC46C685E33C34119233A8" level="section">Sec. 305. Mosquito-borne diseases.</toc-entry>
<toc-entry idref="HF32A8EBEDFFE4C4C8F58384CB5D9C953" level="section">Sec. 306. Epidemiology-laboratory capacity.</toc-entry>
<toc-entry idref="H6F94422FD41D466C8417CEE4D10A9956" level="section">Sec. 307. Supporting public health data availability and access.</toc-entry>
<toc-entry idref="HEE8C7EC35F07466F988A8F3EE19C3D18" level="title">Title IV—Ensuring workforce to prepare for and respond to public health security threats</toc-entry>
<toc-entry idref="H43863B9785EF43C5891614D11DD8BF58" level="section">Sec. 401. Temporary reassignment of State and local personnel during a public health emergency.</toc-entry>
<toc-entry idref="H286B065ECEB045559B83992E9D2ED1B8" level="section">Sec. 402. Epidemic Intelligence Service.</toc-entry>
<toc-entry idref="HF8D8783D759A4E758A4FA7997775455C" level="title">Title V—Addressing drug and supply chain shortages</toc-entry>
<toc-entry idref="H983A7DE34F3141D295236234E79C65C1" level="subtitle">Subtitle A—Ensuring access to lifesaving drugs</toc-entry>
<toc-entry idref="H7FDEE00DF09D4EBEA1E46B5C5D985D01" level="section">Sec. 501. Extended expiration dates for life-saving drugs.</toc-entry>
<toc-entry idref="H9FEEB86555E549B99FD08BB3A234FAB1" level="subtitle">Subtitle B—Drug origin transparency</toc-entry>
<toc-entry idref="H35D1A89F98AB4259B921C8AF8D1B3B76" level="section">Sec. 511. Enhanced drug manufacturing amount information reporting.</toc-entry>
<toc-entry idref="H76CCB82877504603A45781A2D774055B" level="section">Sec. 512. Require drug labeling to include original manufacturer and supply chain information.</toc-entry>
<toc-entry idref="H664ABA704B784C7A94D430A5A2F5A490" level="subtitle">Subtitle C—Medical device shortage reduction</toc-entry>
<toc-entry idref="HF720BCF6768844A081CE21C84751B9A4" level="section">Sec. 521. Clarifying device shortage notifications.</toc-entry>
<toc-entry idref="H120666A2E3834D76A4805DE968426B96" level="section">Sec. 522. Supply chain risk management.</toc-entry>
<toc-entry idref="H4E7FA7EF57564CCD8EFA84331AFA1D04" level="section">Sec. 523. Clarifying voluntary notifications.</toc-entry>
<toc-entry idref="HED39E0CCA7464335B71E4C451302A0B3" level="subtitle">Subtitle D—Drug shortage prevention</toc-entry>
<toc-entry idref="H454C8D961EC34D26982467B39EBE1BE8" level="section">Sec. 531. Improving notification procedures in case of increased demand for critical essential medicines.</toc-entry>
<toc-entry idref="H0B4B0DDCB37E426FB5AE194BB24E8775" level="subtitle">Subtitle E—Protecting Americans from unsafe drugs</toc-entry>
<toc-entry idref="H050DA8F4AE904E9F8F91D57153D12C43" level="section">Sec. 541. Notification, nondistribution, and recall of drugs.</toc-entry></toc></subsection></section>
<title id="H4A0DAC1114604258B02D2CAF3D001FEB"><enum>I</enum><header>Preparing for and responding to public health security threats</header>
<section commented="no" display-inline="no-display-inline" id="H4F4479711B1248FB919FBA718DE42C85" section-type="subsequent-section"><enum>101.</enum><header display-inline="yes-display-inline">National health security strategy</header>
<subsection id="H40FC1EBB9B1646C0B4B1CE3FDE61D1D1"><enum>(a)</enum><header>Public health workforce</header><text display-inline="yes-display-inline">Section 2802(a)(3) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300hh-1">42 U.S.C. 300hh–1(a)(3)</external-xref>) is amended by striking <quote>In 2022, the</quote> and inserting <quote>The</quote>.</text></subsection> <subsection id="H5E70C598E4B54C659AFEE67EB3C69945"><enum>(b)</enum><header>Medical and public health community preparedness goal</header><text display-inline="yes-display-inline">Section 2802(b)(8)(A) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300hh-1">42 U.S.C. 300hh–1(b)(8)(A)</external-xref>) is amended by inserting before the semicolon the following: <quote>, including by protecting against cybersecurity threats</quote>.</text></subsection>
<subsection id="HEF39F944D22146EEB1F31A661486F065"><enum>(c)</enum><header>Cybersecurity resiliency of health care delivery systems</header><text display-inline="yes-display-inline">Section 2802(b) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300hh-1">42 U.S.C. 300hh–1(b)</external-xref>) is amended by adding at the end the following:</text> <quoted-block style="OLC" id="H77CE69B438E9440ABE197569D1678BE3" display-inline="no-display-inline"> <paragraph id="H2889F0F280AF4141870FC68C269CAA22"><enum>(11)</enum><header>Cybersecurity resiliency of health care delivery systems</header><text display-inline="yes-display-inline">Strengthening the ability of States, local communities, Tribal communities, and territorial entities to protect against, mitigate, or otherwise address the impact of cybersecurity risks or cybersecurity attacks that affect public health through mechanisms (including awards of grants or cooperative agreements under section 319C–2) that encourage hospitals and other facilities involved in the delivery of health care items and services to use recognized security practices meeting or exceeding the approaches promulgated under section 405(d) of the Cybersecurity Act of 2015.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section>
<section id="HE2E369993C25430D80C903977A1B84EA"><enum>102.</enum><header>Protection of national security from threats</header><text display-inline="no-display-inline">Section 2811(f)(2)(A) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300hh-10">42 U.S.C. 300hh–10(f)(2)(A)</external-xref>) is amended by striking <quote>$250,000,000 for each of fiscal years 2019 through 2023</quote> and inserting <quote>$327,991,000 for each of fiscal years 2024 through 2028</quote>.</text></section> <section commented="no" display-inline="no-display-inline" id="HB44D71BA14044BA19033CF80265090B0" section-type="subsequent-section"><enum>103.</enum><header display-inline="yes-display-inline">Partnerships for State and regional hospital preparedness to improve surge capacity</header> <subsection id="H442E595425F440A4903DA3D8B120E684"><enum>(a)</enum><header>Authorization of appropriations</header><text>Section 319C–2(j)(1)(A) of the Public Health Service Act (42 U.S.C. 247d–3b(j)(1)(A)) is amended—</text>
<paragraph id="H55106EE2E5064771ADDAF8F4D523BF4E"><enum>(1)</enum><text>by striking <quote>is authorized to be appropriated</quote> and inserting <quote>are authorized to be appropriated</quote>; and</text></paragraph> <paragraph id="H963AA535CB264D2C9B9B4F3F5B63E514"><enum>(2)</enum><text>by inserting <quote> and $500,000,000 for each of fiscal years 2024 through 2028</quote> before the period at the end.</text></paragraph></subsection>
<subsection id="HC181730F8E0644FF92F012005E90AFC8"><enum>(b)</enum><header>Sunset</header><text display-inline="yes-display-inline">Section 319C–2(j)(1)(B)(iii) of the Public Health Service Act (42 U.S.C. 247d–3b(j)(1)(B)(iii)) is amended by striking <quote>2023</quote> and inserting <quote>2028</quote>.</text></subsection></section> <section id="H9B933D8E1CFC4C219C163A034FD995AC"><enum>104.</enum><header>Guidelines for regional health care emergency preparedness and response systems</header> <subsection id="HD84D39AA3A6746F28D26FF37880B6CF1"><enum>(a)</enum><header>Guidelines</header><text display-inline="yes-display-inline">Section 319C–3(b)(3) of the Public Health Service Act (42 U.S.C. 247d–3c(b)(3)) is amended by striking <quote>the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (including any amendments made by such Act)</quote> and inserting <quote>the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, the PREVENT Pandemics Act (title II of division FF of <external-xref legal-doc="public-law" parsable-cite="pl/117/328">Public Law 117–328</external-xref>), and the <short-title>Protecting Pandemic and All-Hazards Preparedness Act of 2023</short-title></quote>.</text></subsection>
<subsection id="H635E3CA0DA5342FCB69104FC1AC691A1"><enum>(b)</enum><header>Demonstration project for regional health care preparedness and response systems</header><text>Section 319C–3(e)(2) of the Public Health Service Act (42 U.S.C. 247d–3c(e)(2)) is amended by striking <quote>2023</quote> and inserting <quote>2028</quote>.</text></subsection></section> <section commented="no" display-inline="no-display-inline" id="H20539C9D239D472ABDF09CCBF9297AC2" section-type="subsequent-section"><enum>105.</enum><header display-inline="yes-display-inline">Strategic National Stockpile</header> <subsection id="H6750084AE5BD4E68A3C1453DE6075428"><enum>(a)</enum><header>Vendor-Managed inventory and warm-Based surge capacity contracts and cooperative agreements with clinical laboratories</header><text>Section 319F–2(a)(5)(A) of the Public Health Service Act (42 U.S.C. 247d–6b(a)(5)(A)) is amended—</text>
<paragraph id="HF88D56AAFEF5423CBFDC113EE95C4FE2"><enum>(1)</enum><text>by inserting after <quote>contracts or cooperative agreements with vendors, which may include manufacturers or distributors of medical products,</quote> the following: <quote>as well as clinical laboratories,</quote>; and</text></paragraph> <paragraph id="HB3DB8D615A7C422AB2F35B9CFCF051EB"><enum>(2)</enum><text>in clause (ii), by striking <quote>domestic manufacturing capacity</quote> and inserting <quote>domestic manufacturing and laboratory capacity</quote>. </text></paragraph></subsection>
<subsection id="H9D471212E3144BA1A890CBBD237258FF"><enum>(b)</enum><header>Authorization of appropriations</header>
<paragraph id="H4A16C5F9201349EA8E30FB70241D0BDC"><enum>(1)</enum><header>In general</header><text>Section 319F–2(f) of the Public Health Service Act (42 U.S.C. 247d–6b(f)) is amended—</text> <subparagraph id="H6BBCD72CEAAA4D89B344EBFAE0A98EE6"><enum>(A)</enum><text display-inline="yes-display-inline">in paragraph (1), by striking <quote>$610,000,000 for each of fiscal years 2019 through 2021, and $750,000,000 for each of fiscal years 2022 and 2023</quote> and inserting <quote>$1,963,000,000 for each of fiscal years 2024 through 2028</quote>;</text></subparagraph>
<subparagraph id="HEE76584BB78546CAAF85E440E29E1DF7"><enum>(B)</enum><text>by striking paragraph (2); and</text></subparagraph> <subparagraph id="H4D53CC1DACF94D3E949FB8467D45BF6E"><enum>(C)</enum><text>by striking <quote><header-in-text level="subsection" style="OLC">Authorization of appropriations</header-in-text></quote> and all that follows through <quote>For the purpose of carrying out subsection (a), there are authorized to be appropriated</quote> and inserting <quote><header-in-text level="subsection" style="OLC">Authorization of appropriations</header-in-text>.—For the purpose of carrying out subsection (a), there is authorized to be appropriated</quote>.</text></subparagraph></paragraph>
<paragraph id="H55725D959FA449378806136848C99535"><enum>(2)</enum><header>Pilot program to support State medical stockpiles</header><text>Section 319F–2(i)(9) of the Public Health Service Act (42 U.S.C. 247d–6b(i)(9)) is amended by striking <quote>2024</quote> and inserting <quote>2028</quote>.</text></paragraph></subsection></section> <section id="HDE1C14AC9FFF431BB19059C10ED726D0" section-type="subsequent-section"><enum>106.</enum><header>Diagnostic testing preparedness plan</header><text display-inline="no-display-inline">The Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/201">42 U.S.C. 201 et seq.</external-xref>) is amended by inserting after section 319F–5 of such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247d-6f">42 U.S.C. 247d–6f</external-xref>) the following:</text>
<quoted-block style="OLC" id="H0A107BD726CB4E8BAACAFDDFFEFE5961" display-inline="no-display-inline">
<section id="H79ADD59E12E747A1AA9D876F175BDB75" section-type="subsequent-section"><enum>319F–6.</enum><header>Diagnostic testing preparedness plan</header>
<subsection id="HB48E01A9E509409DAC96742D4FA3FD63"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary, acting through the Assistant Secretary for Preparedness and Response, and in consultation with the heads of relevant Federal agencies, shall develop not later than 1 year after the date of enactment of this section and update not less than every 3 years thereafter a plan for rapid development, authorization, scaling, procurement, and distribution of diagnostics and clinical and diagnostic laboratory testing capacity during a public health emergency declared under section 319.</text></subsection> <subsection id="H27BB3EBCE39F4A198771B12BD494D732"><enum>(b)</enum><header>Purposes</header><text>The purposes of the plan under subsection (a) shall be—</text>
<paragraph id="H4621FA3813A8419E924DCAE4E64D8B45"><enum>(1)</enum><text display-inline="yes-display-inline">to facilitate the development and utilization of diagnostics for use with respect to a novel chemical, biological, radiological, or nuclear threat or an emerging infectious disease, including any such high-throughput laboratory diagnostic, point-of-care diagnostic, or rapid at-home or point-of-use diagnostic; and</text></paragraph> <paragraph id="HC6C7A8C27AE44CD1BA0923C254984CB9"><enum>(2)</enum><text>to describe the processes for rapid development, authorization, scaling, procurement, and distribution of diagnostics and clinical and diagnostic laboratory testing capacity. </text></paragraph></subsection>
<subsection id="H3091ADE408BA426BA2F058B2CF9B6600"><enum>(c)</enum><header>Public-Private coordination</header>
<paragraph id="H06AB6855AD1E4C8EB2C3712B61934AF9"><enum>(1)</enum><header>In general</header><text>The Secretary, acting through the Assistant Secretary for Preparedness and Response, shall include within the plan under subsection (a) a plan for public-private coordination on national diagnostic testing during a public health emergency.</text></paragraph> <paragraph id="H165B02B112114F1E886A8161E1E00929"><enum>(2)</enum><header>Contents</header><text>The plan under paragraph (1) shall be designed to facilitate coordination and collaboration among—</text>
<subparagraph id="H7AD8F9B86E324EA4A41A6A1EB9EC47E0"><enum>(A)</enum><text>government agencies; and</text></subparagraph> <subparagraph id="H143B7382E78043FA97AC42F25B9819CD"><enum>(B)</enum><text>critical private-sector diagnostic testing stakeholders, including private-sector clinical and diagnostic laboratories, diagnostic manufacturers, health care product distributors, and research laboratories.</text></subparagraph></paragraph></subsection>
<subsection id="H8C31A1F6942F4190BE8F81953E02C4CB"><enum>(d)</enum><header>Public availability</header><text display-inline="yes-display-inline">The Secretary, acting through the Assistant Secretary for Preparedness and Response, shall make the plan under subsection (a) publicly available.</text></subsection> <subsection id="H47AAE23267834CD0AFC5524663B53644"><enum>(e)</enum><header>Reports to Congress</header><text display-inline="yes-display-inline">Not later than 1 year after commencing implementation of the plan under subsection (a) for a public health emergency, the Secretary, acting through the Assistant Secretary for Preparedness and Response, shall submit to the Congress a report evaluating the effectiveness of activities implemented under the plan.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></section>
<section commented="no" display-inline="no-display-inline" id="H3356F683BF9C4731BEAE3E842D6CA4FC" section-type="subsequent-section"><enum>107.</enum><header display-inline="yes-display-inline">Biomedical Advanced Research and Development Authority</header>
<subsection id="H8093EEBDD95E4194BBABF3277DB93C38"><enum>(a)</enum><header>Medical countermeasures for viral threats with pandemic potential</header><text>Section 319L(c)(4) of the Public Health Service Act (42 U.S.C. 247d–7e(c)(4)) is amended—</text> <paragraph id="H7405764F65EB49988ED5768DDE81A691" commented="no" display-inline="no-display-inline"><enum>(1)</enum><text display-inline="yes-display-inline">in subparagraph (D)—</text>
<subparagraph id="HE80A759738AA4652A7EF83B5CAA688DD"><enum>(A)</enum><text>in clause (ii), by striking <quote>; and</quote> and inserting a semicolon;</text></subparagraph> <subparagraph id="H4C6E983862C445E298439822F871ADBA" commented="no" display-inline="no-display-inline"><enum>(B)</enum><text display-inline="yes-display-inline">by redesignating clause (iii) as clause (v); and</text></subparagraph>
<subparagraph id="H29BC2E78B96945CEB031E3B18AFFC2FB"><enum>(C)</enum><text>by inserting after clause (ii) the following:</text> <quoted-block style="OLC" display-inline="no-display-inline" id="HF25E79579A654FBBBBCB61991F5EB4F2"> <clause id="HCE42D1F5E807431AA0B199B92063F646"><enum>(iii)</enum><text display-inline="yes-display-inline">the identification and development of platform manufacturing technologies needed for advanced development and manufacturing of medical countermeasures for viral families which have significant potential to cause a pandemic;</text></clause>
<clause id="H679D1FBA1E7C4251B6E03A2B96F21FED"><enum>(iv)</enum><text display-inline="yes-display-inline">advanced research and development of flexible medical countermeasures against priority respiratory virus families and other respiratory viral pathogens with a significant potential to cause a pandemic, with both pathogen-specific and pathogen-agnostic approaches; and</text></clause><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph></paragraph> <paragraph id="H8BDBC422BAB343A9904AE9707B241173"><enum>(2)</enum><text>in subparagraph (F)—</text>
<subparagraph id="HC7A5342AB7974637AAA10E0C6949AB00"><enum>(A)</enum><text>in clause (ii), by striking <quote>; and</quote> at the end and inserting a semicolon;</text></subparagraph> <subparagraph id="H4D36E1873CDF460A85DDF294C148646B"><enum>(B)</enum><text>in clause (iii), by striking the period and inserting <quote>; and</quote>; and</text></subparagraph>
<subparagraph id="H57EDBADD7A1E47E187424772198090D5"><enum>(C)</enum><text>by adding at the end the following:</text> <quoted-block style="OLC" display-inline="no-display-inline" id="H51FAAC4303FD4B3F928729207F179703"> <clause id="HEFDB724C624B46F181FE7564BF91E765"><enum>(iv)</enum><text>priority virus families and other viral pathogens with a significant potential to cause a pandemic.</text></clause><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph></subsection>
<subsection id="H2CBD8FC41DA44D7180B082B2F4270A64"><enum>(b)</enum><header>Authorization of appropriations</header><text display-inline="yes-display-inline">Section 319L(d)(2) of the Public Health Service Act (42 U.S.C. 247d–7e(d)(2)) is amended by striking <quote>$611,700,000 for each of fiscal years 2019 through 2023</quote> and inserting <quote>$950,000,000 for each of fiscal years 2024 through 2028</quote>.</text></subsection> <subsection id="H2DF4A16AE99A4E3CA7434358A09B44A5" commented="no" display-inline="no-display-inline"><enum>(c)</enum><header>Inapplicability of certain provisions sunset</header><text display-inline="yes-display-inline">Section 319L(e)(1)(D) of the Public Health Service Act (42 U.S.C. 247d–7e(e)(1)(D)) is amended by striking <quote>on the date that is 17 years after the date of enactment of the Pandemic and All-Hazards Preparedness Act</quote> and inserting <quote>on October 1, 2028</quote>.</text></subsection></section>
<section id="H59DBE545497C4319A22E0D93C0AA6127" commented="no" display-inline="no-display-inline"><enum>108.</enum><header>Ensuring collaboration and coordination in medical countermeasure development</header><text display-inline="no-display-inline">Section 319L–1(b) of the Public Health Service Act (42 U.S.C. 274d–7f(b)) is amended by striking <quote>at the end of the 17-year period that begins on the date of enactment of this Act</quote> and inserting <quote>on October 1, 2028</quote>. </text></section> <section id="H4D17EDC4CA3741C4852BF15B2B0D7CC8" section-type="subsequent-section"><enum>109.</enum><header>Review of ASPR efforts to ensure supply chain resiliency and accountability</header> <subsection id="H53D1B60A990741C08D80FF2CA3B9C847"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 18 months after the date of enactment of this Act, the Comptroller General of the United States shall complete a review of—</text>
<paragraph id="H2E8321CEE03E4B9C8A8B932994006F7B"><enum>(1)</enum><text>the Supply Chain Control Tower Program (in this section referred to as the <quote>SCCT Program</quote>) under the Administration for Strategic Preparedness and Response of the Department of Health and Human Services; and</text></paragraph> <paragraph id="HF4FAA940C55848D1A44CCAB9646DA238"><enum>(2)</enum><text>any related efforts of the Administration for Strategic Preparedness and Response—</text>
<subparagraph id="H34B8DA98B6BB4EC09B2E55C12D08A135"><enum>(A)</enum><text display-inline="yes-display-inline">to create supply chain visibility into inventory, capacity, and distribution flow of certain products critical to preparedness and response efforts;</text></subparagraph> <subparagraph id="HF8973D7E67A342D1B4848409D2DB7DDA"><enum>(B)</enum><text display-inline="yes-display-inline">to provide insights into demand forecasting and modeling of certain products critical to preparedness and response efforts; or</text></subparagraph>
<subparagraph id="H583A40E3D85E4FC9B5811C8A75890695"><enum>(C)</enum><text>to inform preparedness and response efforts by targeting distribution and coordinating supply with demand for certain products critical to preparedness and response efforts.</text></subparagraph></paragraph></subsection> <subsection id="HA476A86E95F348B8937E48A6E11DDD5E"><enum>(b)</enum><header>Issues</header><text>The review under this section shall include examination of—</text>
<paragraph id="H65A3DE16CCF941E5B975DBAC6D680AA5"><enum>(1)</enum><text>the data being collected and maintained pursuant to the SCCT Program;</text></paragraph> <paragraph id="H9DE2A995BB9F471B88A8145A7E155652"><enum>(2)</enum><text display-inline="yes-display-inline">how the Department of Health and Human Services, acting through the Administration for Strategic Preparedness and Response, uses such data to provide supply chain visibility and address actual or potential supply gaps;</text></paragraph>
<paragraph id="HA76442FF329944AB8292EA7B5083E1CA"><enum>(3)</enum><text>the extent to which such data is provided and shared with end users, including States, localities, Territories, Tribes, and industry partners;</text></paragraph> <paragraph id="HA67F5409C5D24A39AE596D3A054AC1E5"><enum>(4)</enum><text>the frequency and cadence of data reporting and sharing by and among States, localities, Territories, Tribes, and industry partners;</text></paragraph>
<paragraph id="H9F6390A0B4FC4FBF97105D6EE796DB3F"><enum>(5)</enum><text display-inline="yes-display-inline">information related to the type and number of States, localities, Territories, Tribes, and industry partners participating in the SCCT Program;</text></paragraph> <paragraph id="HF475BA0CAB47453881BB29621553DA8E"><enum>(6)</enum><text display-inline="yes-display-inline">the process by which States, localities, Territories, Tribes, and industry partners voluntarily choose to participate in the SCCT Program; and</text></paragraph>
<paragraph id="H5C7150EC1AB14C7EADC2CD26526A8F18"><enum>(7)</enum><text>any inefficiencies, deficiencies, or challenges related to the application or operation of the SCCT Program.</text></paragraph></subsection> <subsection id="H04360E017E9647B490880A35CFA55226"><enum>(c)</enum><header>Report to Congress</header><text>Not later than the deadline described in subsection (a) for the completion of the review under this section, the Comptroller General shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on the results of such review.</text></subsection></section>
<section id="HE2B115CD84CD4D108A038649C33F88C2"><enum>110.</enum><header>Review of HHS efforts to ensure rapid production and domestic manufacturing capacity of medical countermeasures</header>
<subsection id="HDDE4CB8F81374C43AD2184C9E9EE7A21"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 1 year after the date of the enactment of this Act, the Comptroller General of the United States shall conduct and complete a review examining the efforts of the Secretary of Health and Human Services to ensure that the United States is prepared to rapidly produce qualified countermeasures (as defined in section 319F–1 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247d-6a">42 U.S.C. 247d–6a</external-xref>)) in the event of a public health emergency declared under section 319 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/274d">42 U.S.C. 274d</external-xref>).</text></subsection> <subsection id="HD941834CC88C42A58DA27844D088F3E3"><enum>(b)</enum><header>Contents</header><text>The review conducted under subsection (a) shall include a review of—</text>
<paragraph id="H670AD25EBF0547D9A8BED5C4ECD8FEC5"><enum>(1)</enum><text display-inline="yes-display-inline">the efforts described in such subsection, including the Secretary’s efforts to transition from the Centers for Innovation and Advanced Drug Manufacturing program to any new efforts, including the National Biopharmaceutical Manufacturing Partnership and Industrial Base Expansion Connect; </text></paragraph> <paragraph id="HEE2838B0716746E2A3FA488EB8A28AE6"><enum>(2)</enum><text>the progress made toward the implementation of such efforts; and</text></paragraph>
<paragraph id="H3A4675A84A0A4DC8A380D8EC94E726FE"><enum>(3)</enum><text>the planning within the Department of Health and Human Services to assess risks and challenges associated with advanced development and manufacturing of qualified countermeasures.</text></paragraph></subsection> <subsection id="H21F89C42765B402EA93B53BFF61B3D9B"><enum>(c)</enum><header>Report to Congress</header><text display-inline="yes-display-inline">Not later than 1 year after completing the review under subsection (a), the Comptroller General of the United States shall submit to the Congress a report containing—</text>
<paragraph id="H0BAF8881B29B4A5A8EEDFF87BAD83CAA"><enum>(1)</enum><text>the results of the review; and</text></paragraph> <paragraph id="H87D959B1997A4910A1F8079906554450"><enum>(2)</enum><text display-inline="yes-display-inline">the Comptroller General’s recommendations for ensuring that the United States is prepared to rapidly produce qualified countermeasures in the event of a public health emergency.</text></paragraph></subsection></section>
<section id="H5675F4F3FE7C4980BDE38620392FC133" section-type="subsequent-section"><enum>111.</enum><header>Crisis standards of care</header><text display-inline="no-display-inline">Not later than 2 years after the date of enactment of this Act, the Secretary of Health and Human Services, acting through the Director of the Office for Civil Rights of the Department of Health and Human Services, shall issue guidance on how to develop or modify State and local crisis standards of care for use during an emergency period (as defined in section 1135(g)(1) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1320b-5">42 U.S.C. 1320b–5(g)(1)</external-xref>) so as to bring such standards of care into compliance with the nondiscrimination requirements of section 504 of the Rehabilitation Act of 1973 (<external-xref legal-doc="usc" parsable-cite="usc/29/794">29 U.S.C. 794</external-xref>). </text></section></title> <title id="HB0D5092BA58245A5A402044F27AE18AA"><enum>II</enum><header>Ensuring workforce to prepare for and respond to public health security threats</header> <section commented="no" display-inline="no-display-inline" id="H96C64833473E4826ABE45A86081901C6" section-type="subsequent-section"><enum>201.</enum><header display-inline="yes-display-inline">Emergency system for advance registration of volunteer health professional</header> <subsection commented="no" display-inline="no-display-inline" id="HA8CCD67F47094AD3B18C6A5332D860BB"><enum>(a)</enum><header display-inline="yes-display-inline">In general</header><text display-inline="yes-display-inline">Section 319I(a) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247d-7b">42 U.S.C. 247d–7b</external-xref>) is amended by striking <quote>Not later than 12 months after the date of enactment of the Pandemic and All-Hazards Preparedness Act, the Secretary shall link existing State verification systems to maintain</quote> and inserting <quote>The Secretary shall continue to maintain</quote>.</text></subsection>
<subsection id="HEC45EA3DC36F4EA985E5BE98E1969299"><enum>(b)</enum><header>Authorization of appropriations</header><text>Section 319I(k) of the Public Health Service Act (42 U.S.C. 247d–7b(k)) is amended by striking <quote>2019 through 2023</quote> and inserting <quote>2024 through 2028</quote>.</text></subsection></section> <section id="HBCD978D78A904392A461BA3B452E88CB"><enum>202.</enum><header>Military and civilian partnership for trauma readiness</header><text display-inline="no-display-inline">Section 1291(g) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300d-91">42 U.S.C. 300d–91(g)</external-xref>) is amended by striking <quote>2019 through 2023</quote> and inserting <quote>2024 through 2028</quote>.</text></section>
<section commented="no" display-inline="no-display-inline" id="H953FF3EC862743C0A8B138CC2F02E3BD" section-type="subsequent-section"><enum>203.</enum><header display-inline="yes-display-inline">National advisory committees on disasters</header>
<subsection id="H408DEECF82BA4BF09099DCA35463949A"><enum>(a)</enum><header>National Advisory Committee on Children and Disasters</header><text>Subsection (g) of section 2811A of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300hh-10b">42 U.S.C. 300hh–10b</external-xref>) is amended to read as follows:</text> <quoted-block style="OLC" id="H65BB421B91244B74B7FF64B9D3DF9DE9" display-inline="no-display-inline"> <subsection id="H5ADB3F61E27B4855B724906CEC1FCB1C"><enum>(g)</enum><header>Sunset</header> <paragraph id="H86938C6DFB8B473DB1538B787CD705B5"><enum>(1)</enum><header>In general</header><text>The Advisory Committee shall terminate on September 30, 2028. </text></paragraph>
<paragraph id="H34A7DAF7D1B944A3A8BBE150242D4A7E"><enum>(2)</enum><header>Extension of committee</header><text>Not later than October 1, 2027, the Secretary shall submit to Congress a recommendation on whether the Advisory Committee should be extended.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection> <subsection id="H6A8CA2676D8B4758A30C424F6CE54261"><enum>(b)</enum><header>National Advisory Committee on Seniors and Disasters</header><text>Section 2811B of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300hh-10c">42 U.S.C. 300hh–10c</external-xref>) is amended—</text>
<paragraph id="H49AFA3EAD29E4B0CB61C65C0DEB2BCF2"><enum>(1)</enum><text>in subsection (d)—</text> <subparagraph id="H8982D590CF444D10B73151B6700063C6"><enum>(A)</enum><text display-inline="yes-display-inline">in paragraph (1), by striking <quote>in consultation with such other heads of agencies as appropriate, shall appoint not more than 17 members</quote> and inserting <quote>in consultation with such other Secretaries as may be appropriate, shall appoint not more than 23 members</quote>;</text></subparagraph>
<subparagraph id="HD6EA376E319140D59840844C5204CD49"><enum>(B)</enum><text>by redesignating paragraph (2) as paragraph (3);</text></subparagraph> <subparagraph id="HB1C2234B22074A1D9B99AF739F8ADF32"><enum>(C)</enum><text>by amending paragraph (3), as so redesignated—</text>
<clause id="H503C307DC9BA42DEA3CD8715BA8EA685"><enum>(i)</enum><text>in the paragraph heading, by striking <quote><header-in-text level="paragraph" style="OLC">Required members</header-in-text></quote> and inserting <quote><header-in-text level="paragraph" style="OLC">Required Federal members</header-in-text></quote>;</text></clause> <clause id="HE1A9FD6A0FA34521AF7597EA7DFB7F24"><enum>(ii)</enum><text>in the matter preceding subparagraph (A), by striking <quote>and non-Federal members,</quote>;</text></clause>
<clause id="H0EFF9C578BE142B1BBED7CAF7F7C70D5"><enum>(iii)</enum><text>by striking subparagraphs (J) and (K); and</text></clause> <clause id="HE758A2102449477BB140C55FCDE2DA8C"><enum>(iv)</enum><text>by redesignating subparagraph (L) as subparagraph (J);</text></clause></subparagraph>
<subparagraph id="H283346B8B53446DA820A43ED219B4702"><enum>(D)</enum><text>by inserting after paragraph (1) the following new paragraph:</text> <quoted-block style="OLC" id="H905856E3F2354D8798B70797BFB5EF3D" display-inline="no-display-inline"> <paragraph id="HE47F042526674EFB98C98FB115444927"><enum>(2)</enum><header>Required non-Federal members</header><text display-inline="yes-display-inline">The Secretary, in consultation with such other heads of Federal agencies as may be appropriate, shall appoint to the Advisory Committee under paragraph (1) at least 13 individuals, including—</text>
<subparagraph id="H3078868280704052AB5BFA406C5C54CA"><enum>(A)</enum><text>at least 4 non-Federal health care providers with expertise in geriatric medical disaster planning, preparedness, response, or recovery;</text></subparagraph> <subparagraph id="H39256D3400F44DAA9A0A4CE4D53E468A"><enum>(B)</enum><text>at least 3 representatives of State, local, Tribal, or territorial agencies with expertise in geriatric disaster planning, preparedness, response, or recovery; and</text></subparagraph>
<subparagraph id="H1E02DC499B894FF487F8013C964B855D"><enum>(C)</enum><text>at least 4 non-Federal professionals with training in gerontology, including social workers, scientists, human services specialists, or other non-medical professionals, with experience in disaster planning, preparedness, response, or recovery among other adults.</text></subparagraph></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph> <subparagraph id="H38531AA562064692A78AB0B399E09C45"><enum>(E)</enum><text>by adding at the end the following new paragraphs:</text>
<quoted-block style="OLC" id="H8EEFB3A8B9544EDEBD443FFD1522267D" display-inline="no-display-inline">
<paragraph id="H25EA57643DBA4DA28272A9661EDA44A6"><enum>(4)</enum><header>Term of appointment</header><text display-inline="yes-display-inline">Each member of the Advisory Committee appointed under paragraph (2) shall serve for a term of 3 years, except that the Secretary may adjust the terms of the Advisory Committee appointees serving on the date of enactment of the <short-title>Preparing for All Hazards and Pathogens Reauthorization Act</short-title>, or appointees who are initially appointed after such date of enactment, in order to provide for a staggered term of appointment for all members.</text></paragraph> <paragraph id="HCC1644F14DEE44AAA233AE609C512C1C"><enum>(5)</enum><header>Consecutive appointments; maximum terms</header><text>A member appointed under paragraph (2) may serve not more than 3 terms on the Advisory Committee, and not more than 2 of such terms may be served consecutively.</text></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph></paragraph>
<paragraph id="H653A9C913D0445C5BECB458746A98FCF"><enum>(2)</enum><text>in subsection (g)—</text> <subparagraph id="H88FF670CF43B4689AA17BCE0B0700B6D"><enum>(A)</enum><text>in paragraph (1), by striking <quote>2023</quote> and inserting <quote>2028</quote>; and</text></subparagraph>
<subparagraph id="H0B69B5586B1E45318E9549C6E5F26027"><enum>(B)</enum><text>in paragraph (2), by striking <quote>2022</quote> and inserting <quote>2027</quote>.</text></subparagraph></paragraph></subsection> <subsection id="HF186215BFF4141C3AB543501F829004D"><enum>(c)</enum><header>National Advisory Committee on Individuals with Disabilities</header><text>Section 2811C of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300hh-10d">42 U.S.C. 300hh–10d</external-xref>) is amended—</text>
<paragraph id="HBD7D80F31EC2474DACC7827533833420"><enum>(1)</enum><text>by redesignating subsections (c) through (g) as subsections (d) through (h), respectively;</text></paragraph> <paragraph id="HC625EF80A17A418E90F8F8CCF9ADB975"><enum>(2)</enum><text>by inserting after subsection (b) the following new subsection:</text>
<quoted-block style="OLC" id="HB240F798653D410B838B9146D7D0B895" display-inline="no-display-inline">
<subsection id="H17F42013B7284A2C9DB921AE2EAD3245"><enum>(c)</enum><header>Additional duties</header><text display-inline="yes-display-inline">The Advisory Committee may provide advice and recommendations to the Secretary with respect to individuals with disabilities, and medical and public health grants and cooperative agreements, as applicable to preparedness and response activities under this title and title III.</text></subsection><after-quoted-block>;</after-quoted-block></quoted-block></paragraph> <paragraph id="HA37F3CDB56C34F2F815FEFC2F66B78C9"><enum>(3)</enum><text>in subsection (d), as so redesignated—</text>
<subparagraph id="H560BAF70005D4E1CAD3087D3FD34D236"><enum>(A)</enum><text>in paragraph (1), by striking <quote>in consultation with such other heads of agencies and departments as appropriate, shall appoint not more than 17 members</quote> and inserting <quote>in consultation with such other Secretaries as may be appropriate, shall appoint not more than 23 members</quote>; </text></subparagraph> <subparagraph id="H63071D2209444F3388C50B242DCDF0DD"><enum>(B)</enum><text>by redesignating paragraph (2) as paragraph (3);</text></subparagraph>
<subparagraph id="H1D29E7FA520341BBAB8D08CC763B8252"><enum>(C)</enum><text>by amending paragraph (3), as redesignated—</text> <clause id="H5C5599168C234EE497CBECF3A455BAE2"><enum>(i)</enum><text>in the paragraph heading, by striking <quote><header-in-text level="paragraph" style="OLC">Required members</header-in-text></quote> and inserting <quote><header-in-text level="paragraph" style="OLC">Required Federal members</header-in-text></quote>;</text></clause>
<clause id="HEBFEBCD83D6B4C419A2BEE6107549A02"><enum>(ii)</enum><text>in the matter preceding subparagraph (A), by striking <quote>and non-Federal members,</quote>;</text></clause> <clause id="H98428AC3E51E4D15A9B5392E08A4FCCC"><enum>(iii)</enum><text>by striking subparagraph (K) and inserting the following:</text>
<quoted-block style="OLC" id="HAE74CB02CA66429694A46BA1AE62F253" display-inline="no-display-inline">
<subparagraph id="H5251A9755C164C5F9232999766DE29A4"><enum>(K)</enum><text display-inline="yes-display-inline">Representatives of such other Federal agencies as the Secretary determines necessary to fulfill the duties of the Advisory Committee. </text></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block></clause> <clause id="H68764AA54482417C8E299AA5D94E7FD2"><enum>(iv)</enum><text>by striking subparagraphs (L) and (M); </text></clause></subparagraph>
<subparagraph id="H50070BB2723A4B899EBA4D295E6D8ED3"><enum>(D)</enum><text>by inserting after paragraph (1) the following new paragraph:</text> <quoted-block style="OLC" id="HCAA8EB46FBFC466BBC725FA417CA74AD" display-inline="no-display-inline"> <paragraph id="H51016F510C484DEE941CC681B8ED2A8E"><enum>(2)</enum><header>Required non-Federal members</header><text display-inline="yes-display-inline">The Secretary, in consultation with such other heads of Federal agencies as may be appropriate, shall appoint to the Advisory Committee under paragraph (1) at least 13 individuals, including—</text>
<subparagraph id="H6F59A280F4EC4AC69910CEF488B220E8"><enum>(A)</enum><text display-inline="yes-display-inline">at least 4 non-Federal health care professionals with expertise in disability accessibility before, during, and after disasters, medical and mass care disaster planning, preparedness, response, or recovery;</text></subparagraph> <subparagraph id="HB87EBECB35F84414ABE44958704CE4C7"><enum>(B)</enum><text>at least 3 representatives from State, local, Tribal, or territorial agencies with expertise in disaster planning, preparedness, response, or recovery for individuals with disabilities; and</text></subparagraph>
<subparagraph id="H8B20365EFF7D48D68C0B0DC73CA68BA7"><enum>(C)</enum><text>at least 4 individuals with a disability with expertise in disaster planning, preparedness, response, or recovery for individuals with disabilities.</text></subparagraph></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph> <subparagraph id="H3732BE31972641F6B6F4A518B77517CB"><enum>(E)</enum><text>by adding at the end the following new paragraphs:</text>
<quoted-block style="OLC" id="HB274ECCAE71A4C26B746A6D25D5A9582" display-inline="no-display-inline">
<paragraph id="H221343214DB348D39C0B434851C4F6C9"><enum>(4)</enum><header>Term of appointment</header><text display-inline="yes-display-inline">Each member of the Advisory Committee appointed under paragraph (2) shall serve for a term of 3 years, except that the Secretary may adjust the terms of the Advisory Committee appointees serving on the date of enactment of the <short-title>Preparing for All Hazards and Pathogens Reauthorization Act</short-title>, or appointees who are initially appointed after such date of enactment, in order to provide for a staggered term of appointment for all members.</text></paragraph> <paragraph id="HCFD69BE038A04F569F43562AC29892D6"><enum>(5)</enum><header>Consecutive appointments; maximum terms</header><text>A member appointed under paragraph (2) may serve not more than 3 terms on the Advisory Committee, and not more than 2 of such terms may be served consecutively.</text></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph></paragraph>
<paragraph id="H4BF03E8F543C4DD98ADBCA6ADD0F9BC6"><enum>(4)</enum><text>in subsection (g)—</text> <subparagraph id="H1DCC9E074FD14A738588D121669BB529"><enum>(A)</enum><text>in paragraph (1), by striking <quote>2023</quote> and inserting <quote>2028</quote>; and</text></subparagraph>
<subparagraph id="H1F14B8577D9B424C8A89CEBD2F5F6F7B"><enum>(B)</enum><text display-inline="yes-display-inline">in paragraph (2), by striking <quote>2022</quote> and inserting <quote>2027</quote>.</text></subparagraph></paragraph></subsection></section> <section id="H11240BD8DC084E75A7DA34D88CE6499F" commented="no" display-inline="no-display-inline"><enum>204.</enum><header display-inline="yes-display-inline">National Disaster Medical System</header> <subsection id="HDA2E5614C9814271B5ED61046EBE8305"><enum>(a)</enum><header>Elimination of sunset of authority To make certain appointments for National Disaster Medical System</header><text>Section 2812(c)(4) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300hh-11">42 U.S.C. 300hh–11(c)(4)</external-xref>) is amended—</text>
<paragraph id="H552DED46F46F47B8B473BC4FDDDDC85F"><enum>(1)</enum><text>by striking <quote><header-in-text level="subparagraph" style="OLC"><enum-in-header>(A)</enum-in-header> In general.</header-in-text>—If the Secretary determines</quote> and inserting <quote>If the Secretary determines</quote>; and</text></paragraph> <paragraph id="H28CB6A3D2E1B459A8FFE98A080F87873"><enum>(2)</enum><text>by striking subparagraph (B).</text></paragraph></subsection>
<subsection id="H5EF6F50F35EC48378F77B3284DFF41CF" commented="no" display-inline="no-display-inline"><enum>(b)</enum><header display-inline="yes-display-inline">Authorization of appropriations</header><text display-inline="yes-display-inline">Section 2812(g) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300hh-11">42 U.S.C. 300hh–11(g)</external-xref>) is amended by striking <quote>$57,400,000 for each of fiscal years 2019 through 2023</quote> and inserting <quote>$96,904,000 for each of fiscal years 2024 through 2028</quote>.</text></subsection></section> <section id="HE977F759A3474B4099BE8998EA8F3256" commented="no" display-inline="no-display-inline"><enum>205.</enum><header display-inline="yes-display-inline">Volunteer Medical Reserve Corps</header><text display-inline="no-display-inline">Section 2813(i) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300hh-15">42 U.S.C. 300hh–15(i)</external-xref>) is amended by striking <quote>2019 through 2023</quote> and inserting <quote>2024 through 2028</quote>.</text></section></title>
<title id="H3EB72BACF4D8464AAF530AB7F935AE67"><enum>III</enum><header>Preparing for and responding to public health security threats</header>
<section commented="no" display-inline="no-display-inline" id="HEDC64260F33F4E13A9EAC42F9EFCDAC7" section-type="subsequent-section"><enum>301.</enum><header display-inline="yes-display-inline">Improving State and local public health security</header>
<subsection commented="no" display-inline="no-display-inline" id="HF123251FD4D540F39208FA496BCACA99"><enum>(a)</enum><header display-inline="yes-display-inline">Authorization of appropriations</header><text display-inline="yes-display-inline">Section 319C–1(h)(1)(A) of the Public Health Service Act (42 U.S.C. 247d–3a(h)(1)(A)) is amended by striking <quote>$685,000,000 for each of fiscal years 2019 through 2023</quote> and inserting <quote>$1,000,000,000 for each of fiscal years 2024 through 2028</quote>.</text></subsection> <subsection id="HC0F9843AA47E40018FA6ED13EC30E571"><enum>(b)</enum><header>Elimination of deadwood</header><text display-inline="yes-display-inline">Section 319C–1(h) of the Public Health Service Act (42 U.S.C. 247d–3a(h)) is amended—</text>
<paragraph id="HB2AD187A846248439480C2E89D650341"><enum>(1)</enum><text>by striking paragraphs (4) and (5); and</text></paragraph> <paragraph id="H33B9338F9BFE424FB4F566738E99E560"><enum>(2)</enum><text>by redesignating paragraphs (6) and (7) as paragraphs (4) and (5).</text></paragraph></subsection></section>
<section id="H811F0B9502374F8CA44C04652065CD12"><enum>302.</enum><header>Facilities and capacities of the Centers for Disease Control and Prevention to combat public health security threats</header>
<subsection id="H0CDA0412557F4C3885028CE433DF5362"><enum>(a)</enum><header>Study</header><text display-inline="yes-display-inline">Section 319D(a)(4) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247d-4">42 U.S.C. 247d–4(a)(4)</external-xref>) is amended by striking <quote>Not later than June 1, 2022, the Comptroller General of the United States shall conduct a study on Federal spending in fiscal years 2013 through 2018</quote> and inserting <quote>Not later than June 1, 2027, the Comptroller General of the United States shall conduct a study on Federal spending in fiscal years 2021 through 2026</quote>.</text></subsection> <subsection id="H35EE332700A14E14A4362879484F7A74"><enum>(b)</enum><header>Authorization of appropriations</header><text>Section 319D(h) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247d-4">42 U.S.C. 247d–4(h)</external-xref>) is amended—</text>
<paragraph id="H103B95757FA54037A387CCCD33325719"><enum>(1)</enum><text>in paragraph (1), by striking <quote>$25,000,000 for each of fiscal years 2022 and 2023</quote> and inserting <quote>$40,000,000 for each of fiscal years 2024 through 2028</quote>; and</text></paragraph> <paragraph id="HCA598A31FC6F4AEAA78F551F610614DE"><enum>(2)</enum><text display-inline="yes-display-inline">in paragraph (2), by striking <quote>2022 and 2023</quote> and inserting <quote>2024 through 2028</quote>.</text></paragraph></subsection></section>
<section id="HCA79BE4D146748A5BE699DDD2ACF8905" commented="no" display-inline="no-display-inline"><enum>303.</enum><header display-inline="yes-display-inline">Monitoring and distribution of certain medical countermeasures</header><text display-inline="no-display-inline">Section 319A(e) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247d-1">42 U.S.C. 247d–1(e)</external-xref>) is amended by striking <quote>2019 through 2023</quote> and inserting <quote>2024 through 2028</quote>.</text></section> <section commented="no" display-inline="no-display-inline" id="H76BED0316CBA49C29A05C8967D6A4A26" section-type="subsequent-section"><enum>304.</enum><header display-inline="yes-display-inline">Enhanced control of dangerous biological agents and toxins</header><text display-inline="no-display-inline">Section 351A(m) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262a">42 U.S.C. 262a(m)</external-xref>) is amended by striking <quote>2027</quote> and inserting <quote>2028</quote>. </text></section>
<section id="H7DF821180ACC46C685E33C34119233A8" commented="no" display-inline="no-display-inline"><enum>305.</enum><header display-inline="yes-display-inline">Mosquito-borne diseases</header><text display-inline="no-display-inline">Section 317S(f) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247b-21">42 U.S.C. 247b–21(f)</external-xref>) is amended—</text> <paragraph id="HC82C87AADF924ED5A31A2DAA54F0DEFC"><enum>(1)</enum><text>in paragraph (1), by striking <quote>2019 through 2023</quote> and inserting <quote>2024 through 2028</quote>; and</text></paragraph>
<paragraph id="H8F9C97DB5784445F98D07061FB2160AF" commented="no" display-inline="no-display-inline"><enum>(2)</enum><text display-inline="yes-display-inline">by striking paragraph (3).</text></paragraph></section> <section id="HF32A8EBEDFFE4C4C8F58384CB5D9C953" commented="no" display-inline="no-display-inline"><enum>306.</enum><header display-inline="yes-display-inline">Epidemiology-laboratory capacity</header><text display-inline="no-display-inline">Section 2821(b) (<external-xref legal-doc="usc" parsable-cite="usc/42/300hh-31">42 U.S.C. 300hh–31(b)</external-xref>) is amended by striking <quote>2019 through 2023</quote> and inserting <quote>2024 through 2028</quote>.</text></section>
<section id="H6F94422FD41D466C8417CEE4D10A9956"><enum>307.</enum><header>Supporting public health data availability and access</header>
<subsection id="H7014623A659747CC9DABDBE803BC7B16"><enum>(a)</enum><header>Designation of public health data standards</header><text>Section 2823(a)(2) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300hh-33">42 U.S.C. 300hh–33(a)(2)</external-xref>) is amended by adding at the end the following:</text> <quoted-block style="OLC" id="HF1C12F4A9AC946AF8B11F6C6F4838D3B"> <subparagraph id="HACB553B830B5468FB24627CB1426DA1C"><enum>(D)</enum><header>Selection of data and technology standards</header><text>The standards designated as described in subparagraph (A) may include standards to improve—</text>
<clause id="HA15C1BC0F5014FD6B60B62D157EE332A"><enum>(i)</enum><text>the exchange of electronic health information for—</text> <subclause id="H4E0FF6B3965F4A28910F87A3D4F3EFC2"><enum>(I)</enum><text>electronic case reporting;</text></subclause>
<subclause id="H6BD21208AB7145CE91886B49828B89DE"><enum>(II)</enum><text>syndromic surveillance;</text></subclause> <subclause id="HB8C4FD5571B04726B86ED6610E12B893"><enum>(III)</enum><text>reporting of vital statistics; and</text></subclause>
<subclause id="H4E0B8C0962274A9091E32D20A1C2C4AA"><enum>(IV)</enum><text>reporting test orders and results electronically, including from laboratories;</text></subclause></clause> <clause id="H82B616EB3789416EA3B42F91B84D2C73"><enum>(ii)</enum><text>automated electronic reporting to relevant public health data systems of the Centers for Disease Control and Prevention; and</text></clause>
<clause id="HFD839937EB934E168B1DF242846AABEA"><enum>(iii)</enum><text>such other uses as the Secretary determines appropriate.</text></clause></subparagraph> <subparagraph id="HFE9CA117358043D39E7986E0C54F9B09"><enum>(E)</enum><header>Considerations</header><text>Standards designated under this paragraph shall include standards and implementation specifications necessary to ensure the appropriate capture, exchange, access, and use of information regarding race, ethnicity, sex (including sexual orientation and gender identity), disability status, veteran status, housing status, age, functional status, and other elements.</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection>
<subsection id="HAA7FF4807F2C4254AACA8049D2DEA40F"><enum>(b)</enum><header>Improving information sharing and availability of public health data</header><text>Section 310B of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/242u">42 U.S.C. 242u</external-xref>) is amended to read as follows:</text> <quoted-block style="OLC" id="HC170416CAA7E4C04ACCEB47EBE81F105"> <section id="H0ADD803DBAC840E3ACCEAA5A1FF3786B"><enum>310B.</enum><header>Improving information sharing and availability of public health data</header> <subsection id="HBFFD8F0AB25A49E8A1AEA7601DB1E9B0"><enum>(a)</enum><header>In general</header><text>The Secretary acting through the Director of the Centers for Disease Control and Prevention (in this section referred to as the <quote>Secretary</quote>) may require the reporting of public health and health care data and information to the Centers for Disease Control and Prevention by—</text>
<paragraph id="HB66E1B94A0C4402FA3E4737DFC6291EA"><enum>(1)</enum><text>health care providers and facilities, including pharmacies;</text></paragraph> <paragraph id="H5547707547C44D7EA3ABBC46CE2D38FF"><enum>(2)</enum><text>public health, clinical, and other laboratories and diagnostic testing entities;</text></paragraph>
<paragraph id="H97284CD94B6C49B5BF09CB27DC0C5A0F"><enum>(3)</enum><text>State, local, and Tribal health departments; and</text></paragraph> <paragraph id="H4AF427869A684ABA969354578D8E2DB9"><enum>(4)</enum><text>other entities, as determined appropriate by the Secretary.</text></paragraph></subsection>
<subsection id="H876F00BDBE7A40BE91604C569ADA7636"><enum>(b)</enum><header>Content, form, manner, and frequency</header>
<paragraph id="H762FCE65691F4738987FC6BEAC4744A4"><enum>(1)</enum><header>Collaboration</header><text>The Secretary shall collaborate with representatives of State, local, and Tribal health departments and other entities on determining the content, form, manner, and frequency of the reporting of public health and health care data and information required pursuant to subsection (a).</text></paragraph> <paragraph id="H20F316118AC94DD1844D21D19FDEDC86"><enum>(2)</enum><header>Simultaneous reporting</header><text>In determining the content, form, manner, and frequency of the reporting of public health and health care data and information pursuant to subsection (a), where a disease, condition, or related event is reportable under applicable State or local law, the Secretary shall require the data and information to be reported first or simultaneously to the appropriate State or local jurisdiction.</text></paragraph>
<paragraph id="HC57761F3AC9647BCBEE9EE6D06CAB7F2"><enum>(3)</enum><header>Alignment with standards and implementation specifications</header><text>The content, form, manner, and frequency requirements required pursuant to this section shall align with the standards and implementation specifications adopted by the Secretary under section 3004, where applicable.</text></paragraph> <paragraph id="H9576BAA748BA4F2EB1BAB7F346E70BBF"><enum>(4)</enum><header>Reasonable efforts to limit reporting</header><text>The Secretary shall make reasonable efforts to limit the public health and health care data and information required to be reported under this section to the minimum necessary to accomplish the intended public health purpose.</text></paragraph>
<paragraph id="H5490AA7954664F54993FE93BDF5BD2A8"><enum>(5)</enum><header>Implementation and regulations</header><text>The Secretary—</text> <subparagraph id="H8DC1D33574FB4C4E9DDBB1629BCD8B7D"><enum>(A)</enum><text>may promulgate by regulation the content, form, manner, and frequency in which public health and health care data and information is required to be reported under this section; and</text></subparagraph>
<subparagraph id="H360DE0149AE1457DA0E234136CE5C9A1"><enum>(B)</enum><text display-inline="yes-display-inline">in the event of a public health emergency declared under section 319, or where the Secretary determines there is a significant potential for such an emergency to exist, may issue such requirements—</text> <clause id="H46709103CFE049F488E12CAFC6A241F0"><enum>(i)</enum><text>by guidance in accordance with this section; and</text></clause>
<clause id="HCC3B752AF974407980D58EDF6A0DFF0B"><enum>(ii)</enum><text>without regard to the procedures otherwise required by section 553 of title 5, United States Code.</text></clause></subparagraph></paragraph></subsection> <subsection id="H0B8196F5D69344AFB6AD9A3EFFE8BB3B"><enum>(c)</enum><header>Ensuring that data is accessible in a timely manner to State, local, and Tribal health authorities</header> <paragraph id="H2FAD9A4B369D455E8C775F02AD98B02B"><enum>(1)</enum><header>Collaboration</header><text>The Secretary shall collaborate with representatives of State, local, and Tribal health departments, and entities representing such departments, to ensure that data and information that is collected by the Centers for Disease Control and Prevention pursuant to this section are accessible, as appropriate, in a timely manner, to State, local, and Tribal health authorities.</text></paragraph>
<paragraph id="HAEADB618ED344164B484C5C528384EC5"><enum>(2)</enum><header>Rules of construction</header><text>Nothing in this section shall be construed—</text> <subparagraph id="HE9C3DF7267C1407E88664E4E9CEFE8C4"><enum>(A)</enum><text>to prevent any Federal agency, State, local, or Tribal health department, or other entity from collecting data or information under other applicable law; or</text></subparagraph>
<subparagraph id="H2C8120B2D09242D096F36924FBD0AA3E"><enum>(B)</enum><text>to limit the authority of the Centers for Disease Control and Prevention to share public health surveillance data with State, local, or Tribal health authorities.</text></subparagraph></paragraph> <paragraph id="H74242B803F9F4462BB457344694AA9F0"><enum>(3)</enum><header>Reasonable efforts to reduce reporting burdens and potential duplication</header><text>The Secretary shall make reasonable efforts to collaborate with representatives of Federal agencies and State, local, and Tribal health departments to reduce reporting burdens and potential duplication of reporting requirements. Such efforts may include ensuring simultaneous sharing of data and information described in subsection (b) with State, local, and Tribal public health authorities.</text></paragraph></subsection>
<subsection id="HEE56B21DA80C42CF9CC9B60904FD576A"><enum>(d)</enum><header>Confidentiality and protection of data</header><text display-inline="yes-display-inline">Any identifiable, sensitive information reported to the Centers for Disease Control and Prevention pursuant to this section shall not be further disclosed or provided to any other individual or party, including any party involved in civil, criminal, or administrative litigation, except—</text> <paragraph id="H8994A2FDEF0F4F18A0C3A8A58DD2CC50"><enum>(1)</enum><text>as necessary for public health purposes, including with relevant Federal, State, local, or tribal public health authorities;</text></paragraph>
<paragraph id="H1C953562908344CE859FCF85D7111108"><enum>(2)</enum><text>as required under section 552a(d)(1) of title 5, United States Code;</text></paragraph> <paragraph id="HB80B84339D284606B0A094FE1CC091CE"><enum>(3)</enum><text>as required by applicable Federal laws, excluding instances of disclosure in any Federal, State, or local civil, criminal, administrative, legislative, or other proceeding; or</text></paragraph>
<paragraph id="H0EA11EDE9AB0468382B5AB0835C19788"><enum>(4)</enum><text>with the consent of each individual to whom the information pertains.</text></paragraph></subsection> <subsection id="H2180BAE7BEA345F1BA0EA1529082F7DF"><enum>(e)</enum><header>Exemption of certain public health data from disclosure</header><text display-inline="yes-display-inline">The Secretary may exempt from disclosure under section 552(b)(3) of title 5, United States Code, public health and health care data and information collected by the Centers for Disease Control and Prevention pursuant to this section or any other authority under which the Centers collects public health or health care data and information if—</text>
<paragraph id="HB20D9F6D5BF747C4A2F598D06720A419"><enum>(1)</enum><text>an individual is identified through such data or information; or</text></paragraph> <paragraph id="H9D792112A74B48E5ABAAD9AB7E7C6E40"><enum>(2)</enum><text>there is at least a very small risk, as determined by current scientific practices or statistical methods, that some combination of the data or information, the request for disclosure under such section 552(b)(3), and other available data sources or the application of technology could be used to deduce the identity of the individuals to which such data or information pertains.</text></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></subsection>
<subsection commented="no" display-inline="no-display-inline" id="HF71D4C36759C43B3AF428B546FF9407A"><enum>(c)</enum><header>Public Health Information Sharing and Availability Advisory Committee</header><text>Part A of title III of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/241">42 U.S.C. 241 et seq.</external-xref>) is amended by adding at the end the following:</text> <quoted-block style="OLC" display-inline="no-display-inline" id="H2F099AAEC36B456BB450BD910EB086FC"> <section id="H8549553F26C84D2F8D770C6FFC5F593D"><enum>310C.</enum><header>Public Health Information Sharing and Availability Advisory Committee</header> <subsection id="H40C5CF6BAD3C4F78897B975C4E35DF2D"><enum>(a)</enum><header>Establishment</header><text>The Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall establish an advisory committee, to be known as the Public Health Information Sharing and Availability Advisory Committee, to advise, and make recommendations to, the Director with respect to the implementation of public health and health care data and information reporting and sharing under section 310B.</text></subsection>
<subsection id="H2EA8DDC867E64BF787840FB3D3C0772F"><enum>(b)</enum><header>Membership</header><text>The membership of the advisory committee established pursuant to this section shall include—</text> <paragraph id="H0DF1F9C4305E41B090EA5ACD037DCA59"><enum>(1)</enum><text>individuals with subject matter expertise or experience in the following areas of public health and health care data and information, including—</text>
<subparagraph id="HEB741175CECF4940AFEB75C6ABC04F3E"><enum>(A)</enum><text>State, territorial, local, and Tribal health department data systems or practices; and</text></subparagraph> <subparagraph id="H1E4C67D7E87841DE8FE7120A9EFDB3F2"><enum>(B)</enum><text>health care data;</text></subparagraph></paragraph>
<paragraph id="H91CF038D496941F98C505B1B26009818"><enum>(2)</enum><text>ex officio members, including from relevant Federal agencies such as the Office of the National Coordinator for Health Information Technology, the Centers for Medicare &amp; Medicaid Services, the Centers for Disease Control and Prevention, and the Office of the Assistant Secretary for Health;</text></paragraph> <paragraph id="H79C607E3CEB34C009A7EA86331357016"><enum>(3)</enum><text display-inline="yes-display-inline">representatives of national organizations, including the Council of State and Territorial Epidemiologists, the Association of Public Health Laboratories, the Association of State and Territorial Health Officials, the National Association of County and City Health Officials, and the Big Cities Health Coalition; and</text></paragraph>
<paragraph id="HDF413C18C8A64636BB6EDF382F9C1042"><enum>(4)</enum><text display-inline="yes-display-inline">such additional members as the Secretary determines appropriate.</text></paragraph></subsection> <subsection id="H3870827D59E54CAC8D93117D794C0267"><enum>(c)</enum><header>FACA applicability</header><text>The advisory committee established pursuant to this section is deemed to be an advisory committee subject to the Federal Advisory Committee Act.</text></subsection></section><after-quoted-block>. </after-quoted-block></quoted-block></subsection>
<subsection commented="no" display-inline="no-display-inline" id="HFB9487CD45FA451594E40421B67CA400"><enum>(d)</enum><header>Improving public health data collection</header>
<paragraph id="HEA8CDB62F11D418BB45E08991D2653F0"><enum>(1)</enum><header>In general</header><text>The Secretary of Health and Human Services (referred to in this subsection as the <quote>Secretary</quote>) shall award grants, contracts, or cooperative agreements to eligible entities for purposes of identifying, developing, or disseminating best practices in the collection of electronic health information and the use of designated data standards and implementation specifications—</text> <subparagraph id="HFEA98C8CACF542BCB3E289F493D56DE2"><enum>(A)</enum><text>to improve the quality and completeness of data, including demographic data, collected, accessed, or used for public health purposes; and</text></subparagraph>
<subparagraph id="H7AD3E4C1302A404386850CB10D6385BB"><enum>(B)</enum><text>to address health disparities and related health outcomes.</text></subparagraph></paragraph> <paragraph id="HE2D7AE6154F2454B9878187FDBC760F4"><enum>(2)</enum><header>Eligible entities</header><text>To be eligible to receive an award under this subsection an entity shall—</text>
<subparagraph id="HBF1FE8AB49DE4655B5E6701E5E75CFA4"><enum>(A)</enum><text>be a health care provider, academic medical center, community-based organization, State, local governmental entity, Indian Tribe or Tribal organization (as such terms are defined in section 4 of the Indian Self Determination and Education Assistance Act (<external-xref legal-doc="usc" parsable-cite="usc/25/5304">25 U.S.C. 5304</external-xref>)), Urban Indian organization (as defined in section 4 of the Indian Health Care Improvement Act (<external-xref legal-doc="usc" parsable-cite="usc/25/1603">25 U.S.C. 1603</external-xref>)), or other appropriate public or private nonprofit entity, or a consortia of any such entities; and</text></subparagraph> <subparagraph id="HE3FE3E03CC794E97B7A25EDBA42D8976"><enum>(B)</enum><text>submit an application to the Secretary at such time, in such manner, and containing such information as the Secretary may require.</text></subparagraph></paragraph>
<paragraph id="H40F301BB4C62400AA80C2953388FCF70"><enum>(3)</enum><header>Activities</header><text>Entities receiving awards under this subsection shall use such award to develop and test best practices for training health care providers to use standards and implementation specifications that assist in the capture, access, exchange, and use of electronic health information, including demographic information, disability status, veteran status, housing status, functional status, and other data elements. Such activities shall, at a minimum, include—</text> <subparagraph id="H4AE22229DF5D4FC69A7A78835E9D5D82"><enum>(A)</enum><text>improving, understanding, and using data standards and implementation specifications;</text></subparagraph>
<subparagraph id="H5DD121B7B9ED49B484D566147AF6C71F"><enum>(B)</enum><text>developing or identifying methods to improve communication with patients in a culturally and linguistically appropriate manner, including to better capture information related to demographics of such individuals;</text></subparagraph> <subparagraph id="H12293EE55A2A4880BFF9DC8F4142B666"><enum>(C)</enum><text>developing methods for accurately categorizing and recording patient responses using available data standards;</text></subparagraph>
<subparagraph id="H3598B7ACB40F489084A1ACF660AF77BB"><enum>(D)</enum><text>educating providers regarding the utility of such information for public health purposes and the importance of accurate collection and recording of such data; and</text></subparagraph> <subparagraph id="H637B5888AF1C44C188DC0E29A009F5F5"><enum>(E)</enum><text>other activities, as the Secretary determines appropriate.</text></subparagraph></paragraph>
<paragraph id="H1D6614EA67414FDE9FE6759181A2095F"><enum>(4)</enum><header>Reporting</header>
<subparagraph id="H9DBFECFFE71B490EA0510AA5F5CF7AC5"><enum>(A)</enum><header>Reporting by award recipients</header><text>Each recipient of an award under this subsection shall submit to the Secretary a report on the results of best practices identified, developed, or disseminated through such award.</text></subparagraph> <subparagraph id="H64AA2CA51FB94111BA6C515F0F6BE1F9"><enum>(B)</enum><header>Report to congress</header><text>Not later than 1 year after the completion of the program under this subsection, the Secretary shall submit a report to Congress on the success of the best practices developed under such program, opportunities for further dissemination of such best practices, and recommendations for improving the capture, access, exchange, and use of information to improve public health and reduce health disparities.</text></subparagraph></paragraph>
<paragraph id="HD85E7F52DE3A4F9FB2626823E432001F"><enum>(5)</enum><header>Nonduplication of efforts</header><text>The Secretary shall ensure that the activities and programs carried out under this subsection are free of unnecessary duplication of effort.</text></paragraph> <paragraph id="H4A1D3B265DD34AE293C992BCE80C659C"><enum>(6)</enum><header>Authorization of appropriations</header><text>There is authorized to be appropriated $10,000,000 for each of fiscal years 2024 through 2026 to carry out this subsection.</text></paragraph></subsection>
<subsection id="HC507FE40987A4586A23BD565EC255D3A"><enum>(e)</enum><header>Information collection</header><text>Section 319D(a) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247d-4">42 U.S.C. 247d–4(a)</external-xref>) is amended by adding at the end the following:</text> <quoted-block style="OLC" display-inline="no-display-inline" id="H906803E7959E49299315A927B3DC4422"> <paragraph id="H75EF742313E6442D869DBBAF55E2EE2F"><enum>(5)</enum><header>Information collection</header><text>Subchapter I of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/44/35">chapter 35</external-xref> of title 44, United States Code, shall not apply to information collection by the Centers for Disease Control and Prevention, including the Agency for Toxic Substances and Disease Registry, that are part of investigations, research, surveillance, or evaluations undertaken for public health purposes under any available authority.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section></title>
<title id="HEE8C7EC35F07466F988A8F3EE19C3D18"><enum>IV</enum><header>Ensuring workforce to prepare for and respond to public health security threats</header>
<section commented="no" display-inline="no-display-inline" id="H43863B9785EF43C5891614D11DD8BF58" section-type="subsequent-section"><enum>401.</enum><header display-inline="yes-display-inline">Temporary reassignment of State and local personnel during a public health emergency</header>
<subsection id="HD0CE5A5A0DCA4588BEE1DA884BFB6DE1"><enum>(a)</enum><header>Report to Congress</header><text display-inline="yes-display-inline">Section 319(e)(6) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247d">42 U.S.C. 247d(e)(6)</external-xref>) is amended by striking <quote>Not later than 4 years after the date of enactment of the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013, the Comptroller General of the United States shall</quote> and inserting <quote>Not later than 4 years after the date of enactment of the <short-title>Protecting PAHPA Act of 2023</short-title>, the Comptroller General of the United States shall</quote>.</text></subsection> <subsection id="H6CB8D11FF9A14D6BB3729C839C6F0768"><enum>(b)</enum><header>Sunset</header><text>Section 319(e)(8) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247d">42 U.S.C. 247d(e)(8)</external-xref>) is amended by striking <quote>2023</quote> and inserting <quote>2028</quote>.</text></subsection></section>
<section id="H286B065ECEB045559B83992E9D2ED1B8" commented="no" display-inline="no-display-inline"><enum>402.</enum><header display-inline="yes-display-inline">Epidemic Intelligence Service</header><text display-inline="no-display-inline">Section 317F(c)(2) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247b-7">42 U.S.C. 247b–7(c)(2)</external-xref>) is amended by striking <quote>2019 through 2023</quote> and inserting <quote>2024 through 2028</quote>.</text></section></title> <title id="HF8D8783D759A4E758A4FA7997775455C"><enum>V</enum><header>Addressing drug and supply chain shortages</header> <subtitle id="H983A7DE34F3141D295236234E79C65C1"><enum>A</enum><header>Ensuring access to lifesaving drugs</header> <section id="H7FDEE00DF09D4EBEA1E46B5C5D985D01"><enum>501.</enum><header>Extended expiration dates for life-saving drugs</header> <subsection id="H539402F87D8E497AA60262BD803F4419"><enum>(a)</enum><header>In general</header><text>The Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/301">21 U.S.C. 301 et seq.</external-xref>) is amended by inserting after section 506L of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356l">21 U.S.C. 356l</external-xref>) the following new section:</text>
<quoted-block id="H211BA65EDC3A4501BBE7051A2CDD16A3" style="OLC">
<section id="H8A64538790F94F2CB659D1FF25237089"><enum>506M.</enum><header>Extended expiration dates for life-saving drugs</header>
<subsection id="H013C668B0B0341F38B4FC4377492A12D"><enum>(a)</enum><header>In general</header><text>A manufacturer of a life-saving drug shall—</text> <paragraph id="H70531303D8EC47B783C2CC12BF20DCCA"><enum>(1)</enum><text>submit to the Secretary data and information as required by subsection (b)(1);</text></paragraph>
<paragraph id="H92A25518A59E4CB4A64D08A10BD78BEE"><enum>(2)</enum><text>conduct and submit the results, data, and information generated by any studies required under subsection (b)(2); and</text></paragraph> <paragraph id="HCB1D6F2C86E14DFCB314BA939BAB000A"><enum>(3)</enum><text>make any labeling change described in subsection (c) by the date specified by the Secretary pursuant to such subsection.</text></paragraph></subsection>
<subsection id="H619067AFF6A3442C8C2A5A9C1E74288F"><enum>(b)</enum><header>Data and information</header>
<paragraph id="HD52F4A49F42044D3939F20F3A40DA254"><enum>(1)</enum><header>In general</header><text>The Secretary may issue an order requiring the manufacturer of a life-saving drug to submit, in such manner as the Secretary may prescribe, data and information from any stage of development of the drug that are adequate to assess the stability of the drug to determine the longest supported expiration date.</text></paragraph> <paragraph id="HF4768BFC830B416D8D977D16742CDC51"><enum>(2)</enum><header>Lack of data and information</header><text>If the data and information required pursuant to an order issued under paragraph (1) are not available or are insufficient, as determined by the Secretary, the Secretary may issue an order requiring the manufacturer of the drug—</text>
<subparagraph id="HED08EAF12FAF4A77B24DBFE5DDD3B59A"><enum>(A)</enum><text>to conduct studies, which may be a continuation of ongoing studies, to provide data and information adequate to assess the stability of the drug and to determine the longest supported expiration date; and</text></subparagraph> <subparagraph id="H37382368CB5F4685BAE8A9C66EE78182"><enum>(B)</enum><text display-inline="yes-display-inline">to submit such data and information to the Secretary in such manner as the Secretary may prescribe in the order.</text></subparagraph></paragraph></subsection>
<subsection id="H5B10A67FB510485BB1B318256F0D50ED"><enum>(c)</enum><header>Labeling</header><text>The Secretary may issue an order requiring the manufacturer of a life-saving drug, by a date determined by the Secretary in consultation with the sponsor of the drug, to make any labeling change regarding the expiration date or storage and handling of the drug that the Secretary determines to be appropriate based on the data and information required to be submitted under this section or any other data and information available to the Secretary.</text></subsection> <subsection id="H1FB215108C894EE79D47931E7D4B5769"><enum>(d)</enum><header>Definitions</header><text display-inline="yes-display-inline">In this section:</text>
<paragraph id="H87AC4E73B37540D9ACEBA2A2DE8EE084"><enum>(1)</enum><header>Life-saving drug</header><text>The term <term>life-saving drug</term> means a drug, that is—</text> <subparagraph id="HBB6BE8DDC77341B79992032AEAC43724"><enum>(A)</enum> <clause commented="no" display-inline="yes-display-inline" id="H167BCB938312405FB15A3ADD777A2EBA"><enum>(i)</enum><text>a medical countermeasure; or</text></clause>
<clause id="H4F9B45333250446F9B9791E6A0648026" indent="up1"><enum>(ii)</enum><text display-inline="yes-display-inline">on the drug shortage list under section 506E or determined by the Secretary to be at risk of shortage; and</text></clause></subparagraph> <subparagraph id="HB6F96A4A256C4647B3E977141A6D3AFD"><enum>(B)</enum> <clause commented="no" display-inline="yes-display-inline" id="H8E10ACEA087749DAB898CC70F9CCD376"><enum>(i)</enum><text display-inline="yes-display-inline">life-supporting;</text></clause>
<clause id="H07B8D4AC8C5240C38ADCFC98DAFDF0B7" indent="up1"><enum>(ii)</enum><text>life-sustaining; or</text></clause> <clause id="H28DE44A94E634C588059A54B8563735F" indent="up1"><enum>(iii)</enum><text>intended for use in the prevention or treatment of a debilitating disease or condition in humans or animals, including any such drug used in emergency medical care or during surgery or any such drug that is critical to the public health during a public health emergency declared by the Secretary under section 319 of the Public Health Service Act.</text></clause></subparagraph></paragraph>
<paragraph id="H1267C0554F94414180E3D0BA41A8AB7B"><enum>(2)</enum><header>Medical countermeasure</header><text>The term <term>medical countermeasure</term> means a countermeasure as defined in section 565(a). </text></paragraph></subsection> <subsection id="H556B18F6A834475494D51CB667848744"><enum>(e)</enum><header>Confidentiality</header><text>Nothing in this section shall be construed as authorizing the Secretary to disclose any information that is a trade secret or confidential information subject to section 552(b)(4) of title 5, United States Code, or section 1905 of title 18, United States Code.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></subsection>
<subsection id="HF177B6745FA64ADFB07CC2235CF82B1E"><enum>(b)</enum><header>Prohibited act</header><text display-inline="yes-display-inline">Section 301 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/331">21 U.S.C. 331</external-xref>), as amended by section 3503(a)(1)(A) of division FF of <external-xref legal-doc="public-law" parsable-cite="pl/117/328">Public Law 117–328</external-xref>, is amended by inserting at the end the following new subsection:</text> <quoted-block style="OLC" id="HCDEABEDD14334D96984C736B483FFE6C" display-inline="no-display-inline"> <subsection id="HA8BE856D2F31448A8598BEFF42EFE1DA"><enum>(jjj)</enum><text display-inline="yes-display-inline">The failure to comply with any order issued under section 506M.</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection>
<subsection id="HB5F20FF9F93F4F7F870E3F847A6032C7"><enum>(c)</enum><header>Penalties</header><text display-inline="yes-display-inline">Subsection (b) of section 303 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/333">21 U.S.C. 333</external-xref>) is amended by inserting at the end the following:</text> <quoted-block style="OLC" id="HA832DAA0A7D64BAB9083303605D8F72D" display-inline="no-display-inline"> <paragraph id="H0040C9F22B5C4666BC2311D56E68711D" indent="up1"><enum>(9)</enum><text display-inline="yes-display-inline">If a manufacturer of a life-saving drug fails to submit data and information as required under section 506M(b)(1), fails to conduct or submit the data and information generated by studies as required under section 506M(b)(2), or fails to make a labeling change as required under section 506M(c), such manufacturer shall be subject to a civil penalty of not more than $10,000 for the first day on which the violation occurs and not more than $10,000 for each subsequent day on which the violation is not corrected.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section></subtitle>
<subtitle id="H9FEEB86555E549B99FD08BB3A234FAB1"><enum>B</enum><header>Drug origin transparency</header>
<section id="H35D1A89F98AB4259B921C8AF8D1B3B76"><enum>511.</enum><header>Enhanced drug manufacturing amount information reporting</header>
<subsection id="H4E9C4BCD65A641F5BE5D2A300AFC875D"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 510(j)(3) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360">21 U.S.C. 360(j)(3)</external-xref>) is amended—</text> <paragraph id="HA7B5EFDE473C44B49868540B3B5F129E"><enum>(1)</enum><text>in subparagraph (A), by adding <quote>or (2)</quote> after <quote>paragraph (1)</quote>; and</text></paragraph>
<paragraph id="HED64627897714BE7897C4AFE741039DC"><enum>(2)</enum><text display-inline="yes-display-inline">by adding at the end the following:</text> <quoted-block style="OLC" id="H736ADFBBC0CF4F94A34E7AE8887D8BDD" display-inline="no-display-inline"> <subparagraph id="H8CDC51FB89F84DCBA4F8A80C12AEF03B" indent="up1"><enum>(C)</enum><text display-inline="yes-display-inline">Each report submitted pursuant to subparagraph (A) with respect to a drug shall—</text>
<clause id="HDF4D7D43FA44427FA5EABCE7503B81A0"><enum>(i)</enum><text>include additional information as may be specified by the Secretary in regulation or guidance regarding the supply chain for such drug, such as—</text> <subclause id="HB6EB09A070CF4DA48813673B75506A9F"><enum>(I)</enum><text>the identity of the respective suppliers of each active pharmaceutical ingredient, active pharmaceutical ingredient intermediate, and in-process material used in such manufacture, preparation, propagation, compounding, or processing of the drug; and</text></subclause>
<subclause id="HC15BA8C698F64E64B1FC54F2C8082664"><enum>(II)</enum><text display-inline="yes-display-inline">the respective amounts of such drug that were manufactured, prepared, propagated, compounded, or processed using an active pharmaceutical ingredient, active pharmaceutical ingredient intermediate, and in-process material from each such identified supplier; and</text></subclause></clause> <clause id="H02537307D5A343EEB1EC66A57457AAB4"><enum>(ii)</enum><text>be submitted more frequently than annually, in accordance with a reporting schedule as may be specified by the Secretary in such regulation or guidance, but not more frequently than 4 times per year.</text></clause></subparagraph>
<subparagraph id="HE7D0C86F8B354B3F80C32B1598DF10D6" indent="up1"><enum>(D)</enum><text>Any additional information specified in regulation or guidance pursuant to subparagraph (C) shall be a required element of reports under this paragraph not earlier than 6 months after the date on which such regulation or guidance is issued in final form (and in no event shall the absence of any regulation or guidance issued under subparagraph (C) affect the requirement to report as described in subparagraph (A)).</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection> <subsection id="H9F84BAC0BB10426E847B9A741F1AD78A"><enum>(b)</enum><header>Conforming amendment</header><text>Section 510(j)(3)(B) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/510">21 U.S.C. 510(j)(3)(B)</external-xref>) is amended by striking <quote>subparagraph (A)</quote> and inserting <quote>this paragraph</quote>.</text></subsection></section>
<section id="H76CCB82877504603A45781A2D774055B"><enum>512.</enum><header>Require drug labeling to include original manufacturer and supply chain information</header><text display-inline="no-display-inline">Section 502 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/352">21 U.S.C. 352</external-xref>) is amended—</text> <paragraph id="H729B2E5EFEFA486DB463AC6C460CA3C7"><enum>(1)</enum><text>in paragraph (b)—</text>
<subparagraph id="HFA75B8580D6643BEAB3E63853BE3A182"><enum>(A)</enum><text>by striking <quote>(b) If in a package</quote> and inserting <quote>(b)(1) If in a package</quote>;</text></subparagraph> <subparagraph id="H54A17DE099714134AB9C3592611ADBD1"><enum>(B)</enum><text>by striking <quote>a label containing (1) the name and place</quote> and inserting </text>
<quoted-block style="OLC" id="H9AD0CCA746764CB4BEBF32A3E3564AB8" display-inline="yes-display-inline"><text>a label containing—</text> <paragraph id="H0C4CF1E6FB5D4E92BB5BE85025D90BC7"><enum>(A)</enum><text display-inline="yes-display-inline">the name and place</text></paragraph><after-quoted-block>;</after-quoted-block></quoted-block></subparagraph>
<subparagraph id="HA0C36162127B45098ADC7A5C8439E7E0"><enum>(C)</enum><text display-inline="yes-display-inline">by striking <quote>or distributor; and (2) an accurate statement</quote> and inserting </text> <quoted-block style="OLC" id="H43E2396411AB4194AD45522AB8496892" display-inline="yes-display-inline"><text>or distributor; and </text>
<paragraph id="H73266E1ECC5E425ABC2517BA66D6B754"><enum>(B)</enum><text display-inline="yes-display-inline">an accurate statement</text></paragraph><after-quoted-block>;</after-quoted-block></quoted-block></subparagraph> <subparagraph id="H6C581CC042044043B706AEECD7881295"><enum>(D)</enum><text>by striking <quote>under clause (2) of this paragraph</quote> and inserting <quote>under this clause</quote>; and</text></subparagraph>
<subparagraph id="HE57C05D8DAD24D94B195DCDBDA9FF0BC"><enum>(E)</enum><text>by inserting at the end the following:</text> <quoted-block id="H38CF5989D82E41CFB943E8426E6E7D52" style="OLC"> <paragraph id="H1DF909DFF2DA425E944EAD32BC2A9D27"><enum>(2)</enum> <subparagraph commented="no" display-inline="yes-display-inline" id="H5B43C97D267547FF8307ECB5A976B8B3"><enum>(A)</enum><text display-inline="yes-display-inline">Subject to clause (C), if it is a drug, including an active pharmaceutical ingredient, unless it bears a label containing the name and place of business, and unique facility identifier of the original manufacturer of such drug or active pharmaceutical ingredient, except that the Secretary may provide, by regulation, for reasonable variations in the implementation of such labeling requirements.</text></subparagraph>
<subparagraph id="H2BA6FBE30C364B519812DCE85E8D4AE4" indent="up1"><enum>(B)</enum><text display-inline="yes-display-inline">Subject to clause (C), if it is a drug that is an active pharmaceutical ingredient, unless any accompanying<italic></italic> certificate of analysis contains the name and place of business, and unique facility identifier of the original manufacturer of the active pharmaceutical ingredient.</text></subparagraph> <subparagraph id="H15F9DD294C3A4F6BB4A68A1A8CF83057" indent="up1"><enum>(C)</enum><text display-inline="yes-display-inline">The Secretary may provide, by regulation, for reasonable variations in the implementation of labeling requirements specified in this subparagraph.</text></subparagraph></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph></paragraph>
<paragraph id="HB4ADD8A07DE246518BD1FAF7D72ACF20"><enum>(2)</enum><text>by inserting after paragraph (c) the following:</text> <quoted-block id="H8A8F7EAA08DF4AFEA9E66CAB9FC89CB7" style="OLC"> <subsection id="H7C97417CB63E4BE4A199E330EA1754BE"><enum>(d)</enum> <paragraph commented="no" display-inline="yes-display-inline" id="HD3FBCBA6E9A4499BB20CAE85A954B35A"><enum>(1)</enum><text>Subject to subparagraph (2), if it is a drug, including an active pharmaceutical ingredient, unless it bears labeling containing the name and place of business of—</text>
<subparagraph id="H618ABB2D796F486896CBEE4C63882981" indent="up1"><enum>(A)</enum><text>the original manufacturer of each active pharmaceutical ingredient;</text></subparagraph> <subparagraph id="H09198550067A4CC8BC0B832590DF1652" indent="up1"><enum>(B)</enum><text>each manufacturer, if different from the original manufacturer; and</text></subparagraph>
<subparagraph id="HC81D8F28762D4FF7AC1C4D4BD2043063" indent="up1"><enum>(C)</enum><text>the packer or distributor, if any.</text></subparagraph></paragraph> <paragraph id="HCF59D0DE344D4609A5B7B35FD4FF7351" indent="up1"><enum>(2)</enum><text>The Secretary may provide, by regulation, for reasonable variations or an alternative placement for the labeling requirements specified in subparagraph (1), including by electronic means.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></section></subtitle>
<subtitle id="H664ABA704B784C7A94D430A5A2F5A490"><enum>C</enum><header>Medical device shortage reduction</header>
<section id="HF720BCF6768844A081CE21C84751B9A4"><enum>521.</enum><header>Clarifying device shortage notifications</header><text display-inline="no-display-inline">Section 506J(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356j">21 U.S.C. 356j(a)</external-xref>) is amended—</text> <paragraph id="HF45BC8ACDEDE490D88C74728D76B9930"><enum>(1)</enum><text>in paragraph (2), by striking <quote>during, or in advance of, a public health emergency</quote>; and</text></paragraph>
<paragraph id="HE525677DC9034828996DD1470CC0E873"><enum>(2)</enum><text>in the matter following paragraph (2), by striking <quote>, during, or in advance of, a public health emergency declared by the Secretary under section 319 of the Public Health Service Act,</quote>.</text></paragraph></section> <section id="H120666A2E3834D76A4805DE968426B96"><enum>522.</enum><header>Supply chain risk management</header> <subsection id="H03927B72AB88461A89E15CE1B9350F3D"><enum>(a)</enum><text>Section 506J of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356j">21 U.S.C. 356j</external-xref>) is amended by striking subsection (h) and inserting the following:</text>
<quoted-block id="HD9D998C3683448A189604A2073A37F1D" style="OLC">
<subsection id="HB058690E50CC43F9B5F4051AD71D292D"><enum>(h)</enum><header>Risk management plans</header><text>Each manufacturer of a device described in subsection (a) shall develop, maintain, and, as appropriate, implement a risk management plan that identifies and evaluates risks to the supply of the device, as applicable, for each establishment in which such device is manufactured. Such risk management plan—</text> <paragraph id="H4ADD1CC915B44BEF97568BA76FFD24B5"><enum>(1)</enum><text>may identify and evaluate risks to the supply of more than 1 device, or device category, manufactured at the same establishment; and</text></paragraph>
<paragraph id="HB156C6F714BD414A9CFEADBBA87B2A88"><enum>(2)</enum><text>shall be subject to inspection and copying by the Secretary pursuant to section 704 or at the request of the Secretary.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection> <subsection id="H50774F80998C42E0BB822700B313F3B1"><enum>(b)</enum><header>Conforming amendment</header><text>Section 506J(f) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356j">21 U.S.C. 356j(f)</external-xref>) is amended by striking <quote>or (h)</quote> after <quote>subsection (a)</quote>.</text></subsection></section>
<section id="H4E7FA7EF57564CCD8EFA84331AFA1D04"><enum>523.</enum><header>Clarifying voluntary notifications</header><text display-inline="no-display-inline">Section 506J(i) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356j">21 U.S.C. 356j(i)</external-xref>) is amended by adding at the end the following: <quote>Nothing in this section shall be construed to limit the authority of the Secretary to request that a manufacturer (or other person involved in the device supply chain) provide, on a voluntary basis, information to the Secretary or the authority of the Secretary to receive such information.</quote>.</text></section></subtitle> <subtitle id="HED39E0CCA7464335B71E4C451302A0B3"><enum>D</enum><header>Drug shortage prevention</header> <section id="H454C8D961EC34D26982467B39EBE1BE8"><enum>531.</enum><header>Improving notification procedures in case of increased demand for critical essential medicines</header> <subsection id="H39405C8C22A54492B2C83524AB7CD36E"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 506C of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356c">21 U.S.C. 356c</external-xref>) is amended—</text>
<paragraph id="H6197B9E4941B42A59BFD72F49DD7A277"><enum>(1)</enum><text>in the section heading, by striking <quote><header-in-text level="section" style="OLC">Discontinuance or interruption in the production of life-saving drugs</header-in-text></quote> and inserting <quote><header-in-text level="section" style="OLC">Notification of issues affecting domestic supply of critical essential medicines</header-in-text></quote>;</text></paragraph> <paragraph id="HF696338C3222431093DE1816B404A994"><enum>(2)</enum><text>by striking subsections (a), (b), and (c), and inserting the following:</text>
<quoted-block style="OLC" id="HE0C169CC75BF4721953EEF0FDE386CDF" display-inline="no-display-inline">
<subsection id="HF41B092125BB4A1AB1ED3E4695E8BFD8"><enum>(a)</enum><header>Notification required</header>
<paragraph id="H7DB2D07F8B764D39A89681C11C29C0EB"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">A manufacturer of a critical essential medicine shall notify the Secretary, in accordance with subsection (b), of—</text> <subparagraph id="H44642A148C8448BC83898729F41E3D57"><enum>(A)</enum> <clause commented="no" display-inline="yes-display-inline" id="H4BF387F771E3450484708B53AC782AD4"><enum>(i)</enum><text>a permanent discontinuance in the manufacture of the drug or an interruption of the manufacture of the drug that is likely to lead to a meaningful disruption in the supply of such drug in the United States; </text></clause>
<clause id="H1452BD52AF924A2692803AD37DC3E72D" indent="up1"><enum>(ii)</enum><text display-inline="yes-display-inline">a permanent discontinuance in the manufacture of an active pharmaceutical ingredient, an excipient, or any other input in the final dosage form of such drug or an interruption in the manufacture of the active pharmaceutical ingredient, an excipient, or any other input in the final dosage form of such drug of such drug that is likely to lead to a meaningful disruption in the supply of the active pharmaceutical ingredient of such drug;</text></clause> <clause id="HE9D35764984244BD85A50E89E5FC29FB" indent="up1"><enum>(iii)</enum><text display-inline="yes-display-inline">an increased demand (other than an anticipated seasonal surge) for such drug or an active pharmaceutical ingredient, an excipient, or any other input in the final dosage form of such drug that is likely to lead to a shortage of the drug or the active pharmaceutical ingredient, an excipient, or any other input in the final dosage form of such drug; and</text></clause></subparagraph>
<subparagraph id="H11A358D50C284F2C9295668386E3E38E"><enum>(B)</enum><text display-inline="yes-display-inline">the reasons for such discontinuance, interruption, or increased demand.</text></subparagraph></paragraph> <paragraph id="HC8CD613DEA9949CB8E400752AD95B8A8"><enum>(2)</enum><header>Contents</header><text>Notification under this subsection with respect to a critical essential medicine shall include—</text>
<subparagraph id="H1925FFCCAFC44F229E3356BFD3F17487"><enum>(A)</enum><text display-inline="yes-display-inline">with respect to the reasons for the discontinuation, interruption, or increased demand referred to in paragraph (1)(C), if an active pharmaceutical ingredient, an excipient, or any other input in the final dosage form of such drug is a reason for, or risk factor in, such discontinuation, interruption, or increased demand, the source of the active pharmaceutical ingredient, excipient, or other input and any alternative sources for the an active pharmaceutical ingredient, an excipient, or any other input by the manufacturer;</text></subparagraph> <subparagraph id="H2566407736654D6AA82664FFAE389872"><enum>(B)</enum><text>whether any associated device used for preparation or administration included in the drug is a reason for, or a risk factor in, such discontinuation, interruption, or increased demand; </text></subparagraph>
<subparagraph id="HEBCD81216C484637BF42E25F2B56CF2B"><enum>(C)</enum><text>the expected duration of the interruption or increased demand; and</text></subparagraph> <subparagraph id="H4EC4CD8C15D24E8383B6627C0AB7CC9B"><enum>(D)</enum><text>such other information as the Secretary may require.</text></subparagraph></paragraph></subsection>
<subsection id="H2422F1E3AD6F4D4C993E46D5C840EFAE"><enum>(b)</enum><header>Timing</header>
<paragraph id="H40DB9CDF561A439CA309C2D5E8565FFB"><enum>(1)</enum><header>In general</header><text>A notice required under subsection (a) shall be submitted to the Secretary—</text> <subparagraph id="H8914A66ABBA449C8B1DCE10058E0C3AB"><enum>(A)</enum><text>at least 6 months prior to the date of the discontinuance or interruption; </text></subparagraph>
<subparagraph id="HEE8C253B764D435DAD62641B0C676955"><enum>(B)</enum><text display-inline="yes-display-inline">in the case of such a notice with respect to increased demand for a critical essential medicine, not later than 30 days after the submission of the initial notification under paragraph (2); or</text></subparagraph> <subparagraph id="H9D896596F33845BABDE6D700372A40D8"><enum>(C)</enum><text>if compliance with subparagraph (A) or (B) is not possible, as soon as practicable.</text></subparagraph></paragraph>
<paragraph id="H6DC8188F5A0742C6AF387EB709CFF6E3"><enum>(2)</enum><header>Initial notification with respect to increased demand</header><text display-inline="yes-display-inline">In the case a notification required under subsection (a) with respect to increased demand for a critical essential medicine, the manufacturer of the drug involved shall submit to the Secretary an initial notification not later than 48 hours after the date on which there has been increased demand for the critical essential medicine for a period of at least 6 consecutive weeks. </text></paragraph></subsection> <subsection id="HAACAEEB28B5448ED9983531DAD9D78FE"><enum>(c)</enum><header>Distribution</header><text>To the maximum extent practicable, the Secretary shall distribute, through such means as the Secretary deems appropriate, information on the discontinuance or interruption of the manufacture of, or the increased demand for, critical essential medicines to appropriate organizations, including physician, health provider, and patient organizations, as described in section 506E.</text></subsection><after-quoted-block>; </after-quoted-block></quoted-block></paragraph>
<paragraph id="HECCC427ECBE84D88A2772427DEBA096A"><enum>(3)</enum><text>in subsection (g), in the matter preceding paragraph (1), by striking <quote>drug described in subsection (a)</quote> and inserting <quote>critical essential medicine</quote>; and</text></paragraph> <paragraph id="HBBC30139FDD747D2A0D863D76A2F65FF"><enum>(4)</enum><text>in subsection (j), by striking <quote>drug described in subsection (a)</quote> and inserting <quote>critical essential medicine</quote>.</text></paragraph></subsection>
<subsection id="H600F592044B84AB58861C1CB2476012B"><enum>(b)</enum><header>Application to nonprescription drugs</header><text display-inline="yes-display-inline">Section 506C(h) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356c">21 U.S.C. 356c(h)</external-xref>) is amended—</text> <paragraph id="H206ABFCE1AD04C0396D6597CE8FB7043"><enum>(1)</enum><text>by redesignating paragraphs (1), (2), and (3) as paragraphs (2), (3), and (4), respectively; </text></paragraph>
<paragraph id="H680C83819B05466BB82270B29069B860"><enum>(2)</enum><text>in paragraph (2)(A) (as so redesignated), by striking <quote>and that is subject to section 503(b)(1)</quote> and inserting <quote>, including a drug that is not subject to section 503(b)(1)</quote>; and</text></paragraph> <paragraph id="HA367D100202844A68EC4EC1165308A83"><enum>(3)</enum><text>by inserting before paragraph (2) (as so redesignated) the following: </text>
<quoted-block style="OLC" id="HFFDA54AEF4A94D31A57328AFBA3DD709" display-inline="no-display-inline">
<paragraph id="HD006AE4847DE4B4096ECA97648A2FB57"><enum>(1)</enum><text>the term <term>critical essential medicine</term> means a drug that—</text> <subparagraph id="H110E22DD4CFA466FA0A11F06C0D07A9D"><enum>(A)</enum><text display-inline="yes-display-inline">is—</text>
<clause id="H5231445192E34043932F5B3BC88BFFBF"><enum>(i)</enum><text>life-supporting; </text></clause> <clause id="H816FD6F718D4407B8462591938C9F897"><enum>(ii)</enum><text>life-sustaining; or </text></clause>
<clause id="H1D41682BF41E4CEA956D0F0B711FE419"><enum>(iii)</enum><text>intended for use in the prevention or treatment of a debilitating disease or condition, including any such drug used in emergency medical care or during surgery or any such drug that is critical to the public health during a public health emergency declared by the Secretary under section 319 of the Public Health Service Act; and </text></clause></subparagraph> <subparagraph id="H4F4DC873C813481EA76A33D7021C631C"><enum>(B)</enum><text>is not a radio pharmaceutical drug product or any other product as designated by the Secretary;</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection>
<subsection id="HB91F5B652D5A467191DCFC3DC9DFF6D5"><enum>(c)</enum><header>Regulations</header><text>Not later than 18 months after the date of the enactment of this Act, the Secretary of Health and Human Services shall issue final regulations to implement the amendments made by subsections (a) and (b).</text></subsection> <subsection id="HA80FD7583DFC4975AAB3EA248532131C"><enum>(d)</enum><header>Guidance</header> <paragraph id="H1F902640CEDB40F3B75968FB2E415E08"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall issue guidance on the requirements for notifications required to be submitted under section 506C of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/356c">21 U.S.C. 356c</external-xref>), as amended by subsections (a) and (b), with respect to increased demand for critical essential medicines (as defined in such section 506C). Such guidance shall specifically address—</text>
<subparagraph id="H26AB0EC12F184D33924E43D72A17638B"><enum>(A)</enum><text>the ways in which manufacturers of critical essential medicines can improve demand predictability; </text></subparagraph> <subparagraph id="H69909EFCF27D4B8F96C3C08C9D45BF9A"><enum>(B)</enum><text display-inline="yes-display-inline">what information manufacturers of critical essential medicines should send to the Secretary; and</text></subparagraph>
<subparagraph id="H93FFDF3A68634936AF3A83737D1097F8"><enum>(C)</enum><text>what communications from the manufacturer the Secretary would request with respect to increases in demand following such notifications. </text></subparagraph></paragraph> <paragraph id="HAFD736FB8DB14963913EBC23E80A5460"><enum>(2)</enum><header>Consultation</header><text>In developing such guidance, the Secretary shall consult with relevant stakeholders, including manufacturers of critical essential medicines and local, State, or Federal public health officials. </text></paragraph>
<paragraph id="HD5A5415E63F94D8C9587BA2FFC3C9984"><enum>(3)</enum><header>Timing</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall issue—</text> <subparagraph id="H608D29561E07400EB688938EB50A44AE"><enum>(A)</enum><text>draft guidance under paragraph (1) not later than 120 days after the date of the enactment of this Act; and</text></subparagraph>
<subparagraph id="HBA15FD8CE6D64C3DBC59784CC761BCAB"><enum>(B)</enum><text display-inline="yes-display-inline">final guidance under such paragraph not later than 180 days after the date of the enactment of this Act.</text></subparagraph></paragraph></subsection></section></subtitle> <subtitle id="H0B4B0DDCB37E426FB5AE194BB24E8775"><enum>E</enum><header>Protecting Americans from unsafe drugs</header> <section id="H050DA8F4AE904E9F8F91D57153D12C43" section-type="subsequent-section"><enum>541.</enum><header>Notification, nondistribution, and recall of drugs</header> <subsection id="H82068DE12DF649D085AD1E27C185D557"><enum>(a)</enum><header>Order To cease distribution and recall</header><text>Section 569D of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb-8d">21 U.S.C. 360bbb–8d</external-xref>) is amended—</text>
<paragraph id="H77B975138BC444DDB0211F124BD4535C"><enum>(1)</enum><text>in the section heading, by striking <quote><header-in-text level="section" style="OLC">controlled substances</header-in-text></quote> and inserting <quote><header-in-text level="section" style="OLC">drugs</header-in-text></quote>;</text></paragraph> <paragraph id="H2EE2E1E3F58D491BADAAF2E2CD841FB8"><enum>(2)</enum><text>by striking <quote>controlled substance</quote> each place such term appears and inserting <quote>drug</quote>;</text></paragraph>
<paragraph id="HF8E98A1F37CB40299B4E7DC5C153CF1E"><enum>(3)</enum><text>in subsection (b)—</text> <subparagraph id="H8BAB9ED5724F49C1A7FD5841F5EE6DF1"><enum>(A)</enum><text>by striking <quote>controlled substances</quote> and inserting <quote>drugs</quote>; and</text></subparagraph>
<subparagraph id="HCB4D4A635F66434CB361FC9FEBC08441"><enum>(B)</enum><text>by inserting <quote>of subsection (a)</quote> after <quote>an order pursuant to paragraph (1) or an amended order pursuant to subparagraph (B) or (C) of paragraph (3)</quote>; and</text></subparagraph></paragraph> <paragraph id="H2A1FFDF7B7E54B1AB6DB32118ACEAC9F"><enum>(4)</enum><text>in subsection (c), by striking <quote>or an official senior to such Director</quote> and inserting <quote>or the Director of the Center for Biologics Evaluation and Research (or an official senior to either such Director)</quote>.</text></paragraph></subsection>
<subsection id="HD89C3E923E234890946601E92B0AE650"><enum>(b)</enum><header>Imports and exports</header><text display-inline="yes-display-inline">Section 801(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/381">21 U.S.C. 381(a)</external-xref>), as amended by section 3503(a)(4)(C) of division FF of <external-xref legal-doc="public-law" parsable-cite="pl/117/328">Public Law 117–328</external-xref>, is amended by striking <quote>is a controlled substance subject to an order under section 569D</quote> and inserting <quote>is a drug subject to an order under section 569D</quote>.</text></subsection></section></subtitle></title> </legis-body> </bill> 

